Cencora, Inc 8-K, filed Mar 23, 2021
Cencora, Inc. (COR)
About this 8-K
Cencora, Inc filed this 8-K on March 23, 2021.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): |
__________________________________________
(Exact name of registrant as specified in its charter)
(State or other jurisdiction |
(Commission |
(I.R.S. Employer | ||
| of incorporation) | File Number) | Identification No.) | ||
|
|
| |||
(Address of principal executive offices) |
(Zip Code) |
| Registrant’s telephone number, including area code: | ( |
Not Applicable
____________________________________________
Former name or former address, if changed since last report
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
As previously disclosed in its Current Report on Form 8-K on January 8, 2021, AmerisourceBergen Corporation (the “Company” or “AmerisourceBergen”) entered into a Share Purchase Agreement (the “Share Purchase Agreement”) on January 6, 2021 with Walgreens Boots Alliance, Inc. (“WBA”) pursuant to which the Company will acquire from WBA the majority of WBA’s Alliance Healthcare wholesale distribution businesses, together with certain pre-wholesale and other services, as well as certain of WBA’s retail pharmacy operations (the “Business” or “Alliance Healthcare”) for approximately $6.5 billion, composed of $6.275 billion in cash, subject to certain purchase price adjustments, and 2 million shares of Company common stock.
The Company is filing this Current Report on Form 8-K to provide certain financial information with respect to the Business.
The following audited financial statements of the Business are filed as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference:
| · | Independent Auditors’ Report of Deloitte & Touche LLP; | |
| · | Combined Balance Sheets as of August 31, 2020 and August 31, 2019; | |
| · | Combined Statements of Equity for the years ended August 31, 2020 and August 31, 2019; | |
| · | Combined Statements of Earnings for the years ended August 31, 2020 and August 31, 2019; | |
| · | Combined Statements of Comprehensive Income for the years ended August 31, 2020 and August 31, 2019; | |
| · | Combined Statements of Cash Flows for the years ended August 31, 2020 and August 31, 2019; and | |
| · | Notes to Combined Financial Statements. |
The following unaudited financial statements of the Business are filed as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference:
| · | Unaudited Combined Condensed Balance Sheets as of November 30, 2020 and August 31, 2020; | |
| · | Unaudited Combined Condensed Statements of Equity for the three months ended November 30, 2020 and November 30, 2019; | |
| · | Unaudited Combined Condensed Statements of Earnings for the three months ended November 30, 2020 and November 30, 2019; | |
| · | Unaudited Combined Condensed Statements of Comprehensive Income for the three months ended November 30, 2020 and November 30, 2019; | |
| · | Unaudited Combined Condensed Statements of Cash Flows for the three months ended November 30, 2020 and November 30, 2019; and | |
| · | Notes to Combined Condensed Financial Statements (Unaudited). |
The following unaudited condensed combined pro forma financial statements combining the historical consolidated financial statements of the Company and the Business, reflecting an acquisition of the Business by the Company, are filed as Exhibit 99.3 to this Current Report on Form 8-K and are incorporated herein by reference:
| · | Unaudited Condensed Combined Pro Forma Balance Sheet as of December 31, 2020; | |
| · | Unaudited Condensed Combined Pro Forma Statement of Operations for the year ended September 30, 2020 and for the three months ended December 31, 2020; and | |
| · | Notes to Unaudited Condensed Combined Pro Forma Financial Statements. |
The consent of Deloitte & Touche LLP to the incorporation by reference in the Company’s Registration Statements of Deloitte & Touche LLP’s report dated December 22, 2020, which forms a part of Exhibit 99.1, is filed as Exhibit 23.1 to this Current Report on Form 8-K.
The pro forma financial information included in this Current Report on Form 8-K has been presented for informational purposes only. It does not purport to represent the actual results of operations that the Company and the Business would have achieved had the businesses been combined during the periods presented in the pro forma financial information and is not intended to project the future results of operations that the combined businesses may achieve after the Company’s pending acquisition of the Business is consummated.
Cautionary Note Regarding Forward-Looking Statements
Certain of the statements contained in this Current Report on Form 8-K are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “expect,” “likely,” “outlook,” “forecast,” “would,” “could,” “should,” “can,” “project,” “intend,” “plan,” “continue,” “sustain,” “synergy,” “on track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “possible,” “assume,” variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms; the Company’s ability to consummate the proposed acquisition of WBA’s Alliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or costly than expected; the Company’s or Alliance Healthcare’s failure to achieve expected or targeted future financial and operating performance and results; the effects of disruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and Alliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company’s tax positions and/or the Company’s tax liabilities or adverse resolution of challenges to the Company’s tax positions; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the Company’s operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings; the Company’s ability to manage and complete divestitures; the disruption of the Company’s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company’s business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this report (including in Item 1A (Risk Factors)), (ii) in Item 1A (Risk Factors), in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (iii) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit
|
Description
| |
| 23.1 | Consent of Independent Auditors. | |
| 99.1 | Alliance Healthcare Audited Combined Financial Statements as of August 31, 2020 and August 31, 2019 and for the two years ended August 31, 2020. | |
| 99.2 | Alliance Healthcare Unaudited Combined Condensed Financial Statements as of November 30, 2020 and for the three months ended November 30, 2020. | |
| 99.3 | Unaudited Condensed Combined Pro Forma Financial Statements. | |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL). | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AmerisourceBergen Corporation | ||
| March 23, 2021 | By: | /s/ James F. Cleary |
| Name: James F. Cleary | ||
| Title: Executive Vice President and Chief Financial Officer | ||
Exhibit 23.1
CONSENT OF INDEPENDENT AUDITORS
We consent to the incorporation by reference in Registration Statement No. 333-228489 on Form S-3 and Registration Statement Nos. 333-86012, 333-88230, 333-110431, 333-140470, 333-101042, 333-101043, 333-159924, 333-173982, and 333-194325 on Form S-8 of AmerisourceBergen Corporation of our report dated December 22, 2020, relating to the combined financial statements of certain Pharmaceutical Wholesale and Retail Pharmacy International businesses of Walgreens Boots Alliance, Inc. appearing in this Current Report on Form 8-K dated March 23, 2021.
/s/ Deloitte & Touche LLP
Chicago, Illinois
March 23, 2021
Exhibit 99.1
![]() |
Deloitte & Touche LLP 111 S. Wacker Drive
Tel: +1 312 486 1000 |
INDEPENDENT AUDITORS' REPORT
To the shareholders and the Board of Directors of Walgreens Boots Alliance, Inc.:
We have audited the accompanying combined financial statements of certain Pharmaceutical Wholesale and Retail Pharmacy International businesses of Walgreens Boots Alliance, Inc. (the "Business"), which comprise the combined balance sheet as of August 31, 2020 and 2019, and the related combined statements of equity, earnings, comprehensive income and cash flows for the years then ended, and the related notes to the combined financial statements.
Management's Responsibility for the Combined Financial Statements
Management is responsible for the preparation and fair presentation of these combined financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.
Auditors' Responsibility
Our responsibility is to express an opinion on these combined financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the combined financial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the combined financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the combined financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Business’s preparation and fair presentation of the combined financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Business’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the combined financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the combined financial statements referred to above present fairly, in all material respects, the financial position of certain Pharmaceutical Wholesale and Retail Pharmacy International businesses of Walgreens Boots Alliance, Inc. as of August 31, 2020 and 2019, and the results of their operations and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.
Emphasis of Matter
As described in Note 1, the accompanying combined financial statements have been derived from the accounting records of Walgreens Boots Alliance, Inc. The combined financial statements include the allocation of certain assets, liabilities, expenses and income that have historically been held at the Walgreens Boots Alliance corporate level but which are specifically identifiable or attributable to the Business. The combined financial statements also include expense allocations for certain corporate functions historically provided by Walgreens Boots Alliance, Inc. These costs and allocations may not be reflective of the actual expense which would have been incurred had the Business operated as a separate unaffiliated entity apart from Walgreens Boots Alliance, Inc.
Change in Accounting Principle
As described in Note 2 to the financial statements, effective September 1, 2019, the Business adopted Financial Accounting Standards Board Accounting Standards Update 2016-02, Leases (Topic 842), using the modified retrospective approach which does not require prior periods to be restated.

December 22, 2020
2
WALGREENS BOOTS ALLIANCE
WHOLESALE AND
RETAIL BUSINESSES
COMBINED BALANCE SHEETS
At August 31, 2020
and 2019
(in millions)
| 2020 | 2019 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 143 | $ | 175 | ||||
| Accounts receivable, net | 3,022 | 2,968 | ||||||
| Due from Parent (see Note 12) | 1,557 | 1,419 | ||||||
| Inventories | 1,535 | 1,331 | ||||||
| Other current assets | 376 | 233 | ||||||
| Total current assets | 6,633 | 6,126 | ||||||
| Non-current assets: | ||||||||
| Property, plant and equipment, net | 546 | 530 | ||||||
| Operating lease right-of-use asset | 271 | — | ||||||
| Goodwill | 3,274 | 3,035 | ||||||
| Intangible assets, net | 681 | 712 | ||||||
| Equity method investments | 134 | 127 | ||||||
| Other non-current assets | 97 | 42 | ||||||
| Total non-current assets | 5,003 | 4,446 | ||||||
| Total assets | $ | 11,636 | $ | 10,572 | ||||
| Liabilities and equity | ||||||||
| Current liabilities: | ||||||||
| Short-term debt | $ | 368 | $ | 354 | ||||
| Due to Parent (see Note 12) | 60 | 46 | ||||||
| Trade accounts payable | 4,313 | 4,101 | ||||||
| Operating lease obligation | 68 | — | ||||||
| Accrued expenses and other liabilities | 679 | 442 | ||||||
| Income taxes | 17 | 37 | ||||||
| Total current liabilities | 5,505 | 4,980 | ||||||
| Non-current liabilities: | ||||||||
| Operating lease obligation | 209 | — | ||||||
| Due to Parent (see Note 12) | 864 | 801 | ||||||
| Deferred income taxes | 131 | 133 | ||||||
| Other non-current liabilities | 73 | 85 | ||||||
| Total non-current liabilities | 1,277 | 1,019 | ||||||
| Commitments and contingencies (see Note 8) | ||||||||
| Equity: | ||||||||
| Net Parent investment | 5,814 | 5,848 | ||||||
| Accumulated other comprehensive loss | (1,022 | ) | (1,333 | ) | ||||
| Total equity attributable to the Business | 4,792 | 4,515 | ||||||
| Noncontrolling interests | 62 | 58 | ||||||
| Total equity | 4,854 | 4,573 | ||||||
| Total liabilities and equity | $ | 11,636 | $ | 10,572 | ||||
The accompanying notes to Combined Financial Statements are an integral part of these Statements.
- 1-
WALGREENS BOOTS ALLIANCE
WHOLESALE AND
RETAIL BUSINESSES
COMBINED STATEMENTS OF EQUITY
For the years ended August 31, 2020 and 2019
(in millions)
| Equity attributable to the Business | ||||||||||||||||
| Accumulated | ||||||||||||||||
| other | ||||||||||||||||
| Net Parent | comprehensive | Noncontrolling | Total | |||||||||||||
| investment | income (loss) | interests | equity | |||||||||||||
| August 31, 2018 | $ | 6,007 | $ | (1,093 | ) | $ | 50 | $ | 4,964 | |||||||
| Net earnings | 98 | — | 6 | 104 | ||||||||||||
| Other comprehensive income (loss), net of tax | — | (240 | ) | 2 | (238 | ) | ||||||||||
| Net transfers to Parent | (257 | ) | — | — | (257 | ) | ||||||||||
| August 31, 2019 | 5,848 | (1,333 | ) | 58 | 4,573 | |||||||||||
| Net earnings | 198 | — | 9 | 207 | ||||||||||||
| Other comprehensive income (loss), net of tax | — | 311 | 2 | 313 | ||||||||||||
| Net transfers to Parent | (232 | ) | — | — | (232 | ) | ||||||||||
| Distribution to Noncontrolling interests | — | — | (7 | ) | (7 | ) | ||||||||||
| August 31, 2020 | $ | 5,814 | $ | (1,022 | ) | $ | 62 | $ | 4,854 | |||||||
The accompanying notes to Combined Financial Statements are an integral part of these Statements.
- 2 -
WALGREENS BOOTS ALLIANCE
WHOLESALE AND
RETAIL BUSINESSES
COMBINED STATEMENTS OF EARNINGS
For the years ended August 31, 2020 and 2019
(in millions)
| 2020 | 2019 | |||||||
| Sales | $ | 17,290 | $ | 16,547 | ||||
| Related party sales (see Note 12) | 1,779 | 1,813 | ||||||
| Total Sales | 19,069 | 18,360 | ||||||
| Cost of sales | 17,130 | 16,443 | ||||||
| Gross profit | 1,939 | 1,917 | ||||||
| Selling, general and administrative expenses | 1,620 | 1,708 | ||||||
| Operating income | 319 | 209 | ||||||
| Other expense | (2 | ) | (2 | ) | ||||
| Earnings before interest and income tax provision | 317 | 207 | ||||||
| Interest expense, net | 49 | 77 | ||||||
| Earnings before income tax provision | 268 | 131 | ||||||
| Income tax provision | 71 | 42 | ||||||
| Post tax earnings from equity method investments | 10 | 15 | ||||||
| Net earnings | 207 | 104 | ||||||
| Net earnings attributable to noncontrolling interests | 9 | 6 | ||||||
| Net earnings attributable to the Business | $ | 198 | $ | 98 | ||||
The accompanying notes to Combined Financial Statements are an integral part of these Statements.
- 3 -
WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
COMBINED STATEMENTS
OF COMPREHENSIVE INCOME
For the years ended August 31, 2020 and 2019
(in millions)
| 2020 | 2019 | |||||||
| Comprehensive income: | ||||||||
| Net earnings | $ | 207 | $ | 104 | ||||
| Other comprehensive income (loss), net of tax: | ||||||||
| Pension/postretirement obligations | (3 | ) | (5 | ) | ||||
| Currency translation adjustments | 316 | (233 | ) | |||||
| Total other comprehensive income (loss) | 313 | (238 | ) | |||||
| Total comprehensive income (loss) | 520 | (134 | ) | |||||
| Comprehensive income attributable to noncontrolling interests | 11 | 8 | ||||||
| Comprehensive income (loss) attributable to the Business | $ | 509 | $ | (142 | ) | |||
The accompanying notes to Combined Financial Statements are an integral part of these Statements.
- 4 -
WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
COMBINED
STATEMENTS OF CASH FLOWS
For the years ended August 31, 2020 and 2019
(in millions)
| 2020 | 2019 | |||||||
| Cash flows from operating activities: | ||||||||
| Net earnings | $ | 207 | $ | 104 | ||||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 141 | 143 | ||||||
| Deferred income taxes | (11 | ) | (22 | ) | ||||
| Earnings from equity method investments | (10 | ) | (15 | ) | ||||
| Asset impairment | 19 | 97 | ||||||
| Other | 17 | 15 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | (41 | ) | (367 | ) | ||||
| Inventories | (182 | ) | (99 | ) | ||||
| Other current assets | (108 | ) | (6 | ) | ||||
| Trade accounts payable | 113 | 325 | ||||||
| Accrued expenses and other liabilities | 185 | 67 | ||||||
| Income taxes | (20 | ) | (15 | ) | ||||
| Other non-current assets and liabilities | (58 | ) | 13 | |||||
| Accounts receivable from Parent, net | 75 | (7 | ) | |||||
| Net cash provided by operating activities | 327 | 233 | ||||||
| Cash flows from investing activities: | ||||||||
| Additions to property, plant and equipment | (86 | ) | (104 | ) | ||||
| Net change in cash pool receivable from Parent | (64 | ) | (32 | ) | ||||
| Net change in loan receivable from Parent | (14 | ) | — | |||||
| Other | 6 | 7 | ||||||
| Net cash used for investing activities | (158 | ) | (129 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Net change in short-term debt with maturities of 3 months or less | 27 | 121 | ||||||
| Other | (5 | ) | (1 | ) | ||||
| Net distribution to Parent | (201 | ) | (222 | ) | ||||
| Net cash used for financing activities | (179 | ) | (102 | ) | ||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 2 | (18 | ) | |||||
| Changes in cash, cash equivalents and restricted cash | ||||||||
| Net (decrease) in cash, cash equivalents, and restricted cash | (8 | ) | (16 | ) | ||||
| Cash, cash equivalents and restricted cash at beginning of period | 319 | 335 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 311 | $ | 319 | ||||
The accompanying notes to Combined Financial Statements are an integral part of these Statements.
- 5 -
WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
NOTES TO COMBINED FINANCIAL STATEMENTS
Note 1. Organization, operations and basis of presentation
Organization
These combined financial statements comprise certain pharmaceutical wholesale and retail pharmacy operations (the “Business”) of Walgreens Boots Alliance, Inc. (“WBA”).
Pharmaceutical wholesale operations comprise businesses located in the United Kingdom, France, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Sales within these businesses are principally derived from wholesaling and distribution of a comprehensive offering of brand name and generic pharmaceuticals, health and beauty products, home healthcare supplies and equipment and related services to pharmacies, doctors, health centers and hospitals.
Retail pharmacy operations comprise retail stores in Norway, the Netherlands and Lithuania. Sales within these businesses are principally derived from pharmacy led sales of prescription drugs and health and wellness, beauty and personal care and other consumer products.
Basis of presentation
The Business’s Combined Financial Statements have been prepared on a stand-alone basis and reflect a combination of entities and portions of certain entities under common control that have been “carved out” of and derived from the WBA historical Consolidated Financial Statements and accounting records. Accordingly, WBA’s net investment in this Business (“Net Parent Investment”) is presented in lieu of a controlling interest’s equity in the Combined Financial Statements. Therefore, the Combined Financial Statements reflect the Business’s historical combined financial position, results of operations and cash flows as the Business was historically operated as part of WBA. As a result, the Business’s Combined Financial Statements may not be indicative of the Business’s future performance and do not necessarily reflect what the Business’s combined results of operations, financial condition and cash flows would have been had the Business operated as a separate Business during the periods presented.
The Business is comprised of certain stand-alone legal entities for which discrete financial information is available, as well as portions of legal entities for which discrete financial information is not available (shared legal entities). For the shared legal entities for which discrete financial information was not available, allocation methodologies were applied to certain accounts to allocate amounts to the Business as discussed further in Note 12 – Related parties. The Combined Statements of Earnings include all sales and costs directly attributable to the Business, including costs for facilities, functions and services used by the Business. Certain shared costs and benefits have been directly charged to the Business based on direct usage or other allocation methods.
The Business participates in certain shared cash pool arrangements with WBA but retains a legal right to cash balances swept by WBA. WBA funds the Business’s operating and investing activities as needed. This arrangement is not reflective of the manner in which the Business would have been able to finance its operations had it been a stand-alone business separate from WBA during the periods presented. Cash pooling arrangements along with transfers to and from WBA’s cash management accounts are reflected in the Combined Balance Sheets as current amounts Due to and Due from Parent, and in the Combined Statements of Cash Flows as net investing activities. These Due to and Due from Parent balances are expected to be settled in the ordinary course of business.
The Combined Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The Business uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All transactions between the entities comprising the Business have been eliminated. As described in Note 12 – Related parties, all significant transactions between the Business and WBA have been included in these Combined Financial Statements.
The combined operations of the Business are treated as if it was a separate taxpayer following the separate return methodology. See Note 9 – Income taxes.
The preparation of the Combined Financial Statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. These estimates are based on the information available at the time, historical experience and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of coronavirus COVID-19 ("COVID-19"). Significant estimates inherent in the preparation of these Combined Financial Statements include, but are not limited to, accounting for inventory, evaluation of goodwill and other assets for impairment, income taxes and other contingencies.
- 6 -
To the extent to which COVID-19 impacts the Business’s financial results will depend on numerous evolving factors including, but not limited to, the severity and duration of COVID-19, the extent to which it will impact the Business’s customers, team members, suppliers, vendors, business partners, and distribution channels.
Management of the Business have evaluated subsequent events through December, 22, 2020 which is the date of issuance or the date on which the financial statements were available to be issued.
Certain amounts in the Combined Financial Statements and associated notes may not foot due to rounding.
Note 2. Summary of major accounting policies
Cash and cash equivalents
Cash and cash equivalents include cash on hand and highly liquid investments with an original maturity of three months or less.
Restricted cash
The Business is required to maintain certain cash deposits with banks mainly consisting of deposits restricted under contractual agency agreements and cash restricted by law and other obligations. At August 31, 2020 and 2019, the amount of such restricted cash was $168 million and $144 million, respectively, and is reported in other current assets on the Combined Balance Sheets.
The following represents a reconciliation of cash and cash equivalents in the Combined Balance Sheets to total cash, cash equivalents and restricted cash in the Combined Statements of Cash Flows as of August 31, 2020 and 2019, (in millions):
| August 31, 2020 | August 31, 2019 | |||||||
| Cash and cash equivalents | $ | 143 | $ | 175 | ||||
| Restricted cash (included in other current assets) | 168 | 144 | ||||||
| Cash, cash equivalents and restricted cash | $ | 311 | $ | 319 | ||||
Accounts receivable
Accounts receivable are stated net of allowances for doubtful accounts. Accounts receivable balances primarily consist of trade receivables due from customers, clients and members. Trade receivables were $2.9 billion at August 31, 2020 and August 31, 2019. Other accounts receivable balances consist primarily of receivables from vendors and manufacturers. The carrying values of trade accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.
Charges to allowance for doubtful accounts are based on estimates of recoverability using both historical write-offs and specifically identified receivables. The allowance for doubtful accounts for trade receivables at August 31, 2020 and August 31, 2019 was $35 million and $28 million, respectively.
Factoring arrangements
The Business entered into factoring agreements with various European financial institutions to sell accounts receivable under non-recourse agreements, transferring effective control and risk related to the receivables. These transactions are treated as a sale and were accounted for as a reduction in accounts receivable. The cost of factoring such accounts receivable, is reflected in the Combined Statement of Earnings within Selling, general and administrative expenses. The Business expects to continue to use this factoring arrangement periodically to assist with our general working capital requirements.
Inventories
The Business values inventories on a lower of cost and net realizable value basis. Inventories include product costs, inbound freight, warehousing costs for retail pharmacy operations, direct labor and distribution of products and vendor allowances not classified as a reduction of advertising expense. Substantially all of the Business’s inventory is accounted for using the first in first out method.
Property, plant and equipment
Property, plant and equipment are stated at cost less accumulated depreciation. Major repairs, which extend the useful life of an asset, are capitalized; routine maintenance and repairs are charged against earnings. Depreciation is provided on a straight-line basis over the estimated useful lives of owned assets. Leasehold improvements, equipment under finance lease and finance lease properties are amortized over their respective estimate of useful life or over the term of the lease, whichever is shorter.
- 7 -
The following table summarizes the Business’s property, plant and equipment (in millions) and estimated useful lives (in years):
| Estimated useful life | 2020 | 2019 | ||||||||||
| Land and land improvements | 20 | $ | 96 | $ | 93 | |||||||
| Buildings and building improvements | 3 to 50 | 208 | 192 | |||||||||
| Fixtures and equipment | 3 to 20 | 374 | 327 | |||||||||
| Capitalized system development costs and software | 3 to 8 | 201 | 178 | |||||||||
| 879 | 790 | |||||||||||
| Less: accumulated depreciation and amortization | 333 | 260 | ||||||||||
| Balance at end of year | $ | 546 | $ | 530 | ||||||||
The Business capitalizes application development stage costs for internally developed software. These costs are amortized over a three to eight- year period. Amortization expense for capitalized system development costs and software was $14 million in fiscal 2020 and $15 million in fiscal 2019. Unamortized costs were $111 million at August 31, 2020 and $103 million at August 31, 2019. The Business impaired $16 million and $96 million of previously capitalized system development costs in fiscal 2020 and 2019, respectively, relating to write down of certain software as part of a transformational cost management program (the “Transformational Cost Management Program”), as discussed in Note 3 - Exit and disposal activities.
Depreciation and amortization expense for property, plant and equipment, including capitalized system development costs and software, was $64 million in fiscal 2020 and fiscal 2019.
Leases
The Business determines if an arrangement contains a lease at the inception of a contract. The lease classification is determined at the commencement date. Right-of-use assets represent the Business’s right to use an underlying asset for the lease term and lease liabilities represent the Business’s obligation to make lease payments arising from the lease during the lease term. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the remaining future minimum lease payments during the lease term. The commencement date of all lease terms is the earlier of the date the Business becomes legally obligated to make rent payments or the date the Business has the right to control the property. The Business utilizes its incremental borrowing rate to discount the lease payments. The incremental borrowing rate is based on the Business’s estimated rate of interest for a collateralized borrowing over a similar term as the lease term. The operating lease right-of-use assets also include lease payments made before commencement, lease incentives and are recorded net of impairment. Operating leases are expensed on a straight-line basis over the lease term.
Initial terms for leased premises are typically 5 to 15 years. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet.
The Business accounts for lease components and non-lease components as a single lease component. Variable lease payment amounts that cannot be determined at the commencement of the lease such as increases in lease payments based on changes in index rates or usage, are not included in the right-of-use assets or lease liabilities. These are expensed as incurred. The Business has real estate leases which require additional payments for reimbursement of real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs and hence are not included in the lease payments used to calculate lease liability. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right- of-use assets and lease liabilities. The Business does not separately account for the land portion of the leases involving land and building.
Finance leases are recognized within property, plant and equipment and as a finance lease liability within accrued expenses and other liabilities and other noncurrent liabilities. Finance lease obligations as of August 31, 2020 and 2019 was $10 million and $13 million respectively.
See Note 4 - Leases for further information.
Goodwill and indefinite-lived intangible assets
Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in business combinations. Acquired intangible assets are recorded at fair value.
- 8 -
Goodwill and indefinite-lived intangible assets are evaluated for impairment annually during the fourth quarter, or more frequently if an event occurs or circumstances change that could more-likely-than-not reduce the fair value of a reporting unit or intangible asset below its carrying value. As part of the Business’s impairment analysis, fair value of a reporting unit is determined using both the income and market approaches. The income approach requires management to estimate a number of factors for each reporting unit, including projected future operating results, economic projections, anticipated future cash flows and discount rates. The market approach estimates fair value using comparable marketplace fair value data from within a comparable industry grouping. Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized and the asset is written down to its estimated fair value.
See Note 6 - Goodwill and other intangible assets, for additional disclosure regarding the Business’s intangible assets.
Equity method investments
The Business uses the equity method of accounting for equity investments if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. The Business’s proportionate share of the net income or loss of these investees is included in combined net earnings. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Business’s ownership interest, legal form of the investee, representation on the board of directors, participation in policy-making decisions and material intra-entity transactions. The Business’s ownership percentage as of August 31, 2020 and 2019 for equity method investments ranges from 30% to 49%.
The Business evaluates equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by the Business when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than cost, the investee’s financial condition and near- term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.
See Note 5 - Equity method investments, for further information.
Pensions
The Business has country-specific defined benefit pension plans. Eligibility and the level of benefits for these plans vary reflecting participants’ status, date of hire and/or length of service and requirements of the local markets. Where permissible under local regulations and market requirements, these plans have been closed to new members or future service accrual (to be replaced by defined contribution schemes). Pension expenses and valuations are dependent on assumptions used by third-party actuaries in calculating those amounts. These assumptions include discount rates, expected return on assets, retirement rates, mortality expectations and other factors.
The Business funds its pension plans in accordance with applicable regulations. The Business records the service cost component of net pension cost in selling, general and administrative expenses.
See Note 10 - Retirement benefits for further information.
Noncontrolling interests
The Business presents noncontrolling interests as a component of equity on its Combined Balance Sheets and reports the portion of its earnings or loss for noncontrolling interests as net earnings attributable to noncontrolling interests in the Combined Statements of Earnings.
Currency
Assets and liabilities of non-U.S. dollar functional currency operations are translated into U.S. dollars at end-of-period exchange rates while revenues, expenses and cash flows are translated at average monthly exchange rates over the period. Equity is translated at historical exchange rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss) in the Combined Balance Sheets.
Assets and liabilities not denominated in the functional currency are remeasured into the functional currency at end-of-period exchange rates, except for nonmonetary balance sheet amounts, which are remeasured at historical exchange rates. Revenues and expenses are recorded at average monthly exchange rates over the period, except for those expenses related to nonmonetary balance sheet amounts, which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are generally included in selling, general and administrative expenses within the Combined Statements of Earnings. For all periods presented, there were no material operational gains or losses from foreign currency transactions.
- 9 -
Commitments and contingencies
On a quarterly basis, the Business assesses its liabilities and contingencies for outstanding legal proceedings and reserves are established on a case-by-case basis for those legal claims for which management concludes that it is probable that a loss will be incurred and that the amount of such loss can be reasonably estimated. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. With respect to litigation and other legal proceedings where the Business has determined that a loss is reasonably possible, the Business may be unable to estimate the amount or range of reasonably possible loss due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Business’s assessments are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause the Business to change those estimates and assumptions. Therefore, it is possible that an unfavorable resolution of one or more pending litigation or other contingencies could have a material adverse effect on the Business’s Combined Financial Statements in a future fiscal period. Management’s assessment of current litigation and other legal proceedings, including the corresponding accruals, could change because of the discovery of facts with respect to legal actions or other proceedings pending against the Business which are not presently known. Adverse rulings or determinations by judges, juries, governmental authorities or other parties could also result in changes to management’s assessment of current liabilities and contingencies. Accordingly, the ultimate costs of resolving these claims may be substantially higher or lower than the amounts reserved.
See Note 8 - Commitments and contingencies for further information.
Revenue recognition
Sales are recognized at an amount that reflects the consideration to which the Business expects to be entitled in exchange for transferring control of goods or services to the customer. Sales are reported on the gross amount billed to a customer less discounts if the Business has earned revenue as a principal from the sale of goods and services. Sales are reported on the net amount retained (that is, the amount billed to the customer less the amount paid to a vendor) if the Business has earned a commission or a fee as an agent.
Wholesale revenue is recognized, net of taxes and expected returns, upon shipment of goods, which is generally also the day of delivery. For the retail operations, the Business recognizes revenue, net of taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer.
Cost of sales
Cost of sales includes the purchase price of goods and cost of services rendered, store and warehouse inventory loss, inventory obsolescence and supplier rebates. In addition to product costs, cost of sales includes warehousing costs for retail operations, purchasing costs, freight costs, cash discounts and vendor allowances.
Vendor allowances and supplier rebates
Vendor allowances are principally received as a result of purchases, sales or promotion of vendors’ products. Allowances are generally recorded as a reduction of inventory and are recognized as a reduction of cost of sales when the related merchandise is sold. Allowances received for promoting vendors’ products are offset against advertising expense and result in a reduction of selling, general and administrative expenses to the extent of advertising costs incurred, with the excess treated as a reduction of inventory costs.
Rebates or refunds received by the Business from its suppliers, mostly in cash, are considered as an adjustment of the prices of the suppliers’ products purchased by the Business.
Selling, general and administrative expenses
Selling, general and administrative expenses mainly consist of salaries and employee costs, occupancy costs, depreciation and amortization, expenses directly related to stores, advertising costs (net of vendor advertising allowances), wholesale costs and insurance.
Impairment of long-lived assets
The Business evaluates the recoverability of long-lived assets whenever events or changes in circumstances indicate that the carrying value of such an asset may not be recoverable. The evaluation of long-lived assets is performed at the lowest level of identifiable cash flows. Long-lived assets related to the Business’s retail operations include property, plant and equipment, definite-lived intangibles, right of use asset as well as operating lease liability. If the asset group fails the recoverability test, then an impairment charge is determined based on the difference between the fair value of the asset group compared to its carrying value. Fair value of the asset group is generally determined using income approach based on cash flows expected from the use and eventual disposal of the asset group.
Impairment charges included in selling, general and administrative expenses that relate to the write down of certain software as part of the Transformational Cost Management Program, aggregated to $19 million and $97 million in fiscal 2020 and 2019, respectively, and are discussed in Note 3 - Exit and disposal activities.
- 10 -
The determination of the fair value of the asset group requires management to estimate a number of factors including anticipated future cash flows and discount rates. Although management believes these estimates are reasonable, actual results could differ from those estimates due to the inherent uncertainty involved in making such estimates.
Stock compensation plans
The Business’s employees participate in WBA’s stock compensation plans. Stock based compensation is measured at fair value at the grant date. WBA grants stock options, performance shares and restricted units to the Business’s employees. The Business recognizes compensation expense on a straight-line basis over the substantive service period.
Total stock-based compensation expense attributable to the Business’s employees was $6 million for fiscal 2020 and fiscal 2019.
Insurance
WBA obtains insurance coverage with third-party carriers on behalf of the Business for catastrophic exposures as well as those risks required by law to be insured. The Business regularly reviews the probable outcome of any claims and proceedings, the expenses expected to be incurred, the availability and limits of the insurance coverage and the established accruals for liabilities, making adjustments to amounts provided for as necessary.
Income taxes
The combined operations of the Business are treated as if it was a separate taxpayer (i.e., following the separate return methodology), domiciled in the Netherlands. The Business accounts for income taxes according to the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured pursuant to tax laws using rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more-likely-than-not to be realized.
In determining the income tax provision, the Business uses income, permanent differences between book and tax income, enacted statutory income tax rates and unrecognized tax benefits related to current year results. Discrete events such as the assessment of the ultimate outcome of tax audits, audit settlements, recognizing previously unrecognized tax benefits due to lapsing of the applicable statute of limitations, recognizing or de-recognizing benefits of deferred tax assets due to future year financial statement projections and changes in tax laws are recognized in the period in which they occur.
The Business is subject to routine income tax audits that occur periodically in the normal course of business. Tax authorities may raise questions regarding the Business’s tax filing positions, including the timing and amount of deductions and the allocation of income among various tax jurisdictions. In evaluating the tax benefits associated with the various tax filing positions, the Business records a tax benefit for uncertain tax positions using the highest cumulative tax benefit that is more-likely-than-not to be realized. Adjustments are made to the liability for unrecognized tax benefits in the period in which the Business determines the issue is effectively settled with the tax authorities, the statute of limitations expires for the return containing the tax position or when more information becomes available.
New accounting pronouncements
Adoption of new accounting pronouncements
Intangibles – goodwill and other – internal-use software
In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40). This ASU addresses customer’s accounting for implementation costs incurred in a cloud computing arrangement that is a service contract and also adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The amendment aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The Business early adopted this new accounting standard on September 1, 2019 on a prospective basis. The adoption of this ASU did not have a material impact on the Business’s results of operations or financial position.
- 11 -
Leases
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes Topic 840, Leases. Subsequently, the FASB has issued additional ASUs which further clarify this guidance. This ASU increases the transparency and comparability of organizations by requiring the capitalization of substantially all leases on the balance sheet and disclosures of key information about leasing arrangements. Under this new guidance, at the lease commencement date, a lessee recognizes a right-of-use asset and lease liability, which is initially measured at the present value of the future lease payments. For income statement purposes, a dual model was retained for lessees, requiring leases to be classified as either operating or finance leases. Under the operating lease model, lease expense is recognized on a straight-line basis over the lease term. Under the finance lease model, interest on the lease liability is recognized separately from amortization of the right- of-use asset. In addition, a new ASU was issued in July 2018, to provide relief to companies from restating the comparative periods.
The Business adopted this new accounting standard on September 1, 2019 on a modified retrospective basis and applied the new standard to all leases. As a result, comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods. The Business elected a package of practical expedients permitted under the transition guidance, which among other things, allows the carryforward of historical lease classification. The adoption of this new accounting standard resulted in recognition of lease liabilities of $267 million and recognition of right-of-use assets of $265 million net of lease incentives and prepaid rent as of September 1, 2019. See Note 4 – Leases for further information.
The impact to the Business’s opening Combined Balance Sheets as of September 1, 2019 was as follows (in millions):
| As revised | ||||||||||||
| As reported | September 1, | |||||||||||
| August 31, 2019 | Adjustments | 2019 | ||||||||||
| Combined Balance Sheets | ||||||||||||
| Other current assets | $ | 233 | $ | (2 | ) | $ | 231 | |||||
| Total current assets | 6,126 | (2 | ) | 6,124 | ||||||||
| Property, plant and equipment, net | 530 | — | 530 | |||||||||
| Operating lease right-of-use asset | — | 265 | 265 | |||||||||
| Intangible assets, net | 712 | (3 | ) | 709 | ||||||||
| Total assets | $ | 10,572 | $ | 260 | $ | 10,832 | ||||||
| Operating lease obligation - current | — | 62 | 62 | |||||||||
| Accrued expenses and other liabilities | 442 | (1 | ) | 441 | ||||||||
| Total current liabilities | 4,980 | 61 | 5,041 | |||||||||
| Operating lease obligation – non-current | — | 205 | 205 | |||||||||
| Deferred income taxes | 133 | — | 133 | |||||||||
| Other non-current liabilities | 85 | (6 | ) | 79 | ||||||||
| Total non-current liabilities | 1,019 | 199 | 1,218 | |||||||||
| Net parent investment | 5,848 | — | 5,848 | |||||||||
| Total liabilities and equity | $ | 10,572 | $ | 260 | $ | 10,832 | ||||||
New accounting pronouncements not yet adopted
Effects of Reference Rate Reform on Financial Reporting
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates ("IBORs") and, particularly, the risk of cessation of the London Interbank Offered Rate ("LIBOR"), regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. The ASU can be adopted no later than December 1, 2022 (fiscal 2023) with early adoption permitted. The Business is evaluating the effect of adopting this new accounting guidance.
- 12 -
Financial Instruments
In March 2020, FASB issued ASU 2020-03. This ASU improves and clarifies various financial instruments topics, including the current expected credit losses ("CECL") standard issued in 2016. The ASU includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The amendments have different effective dates. The Business is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Business’s financial statements.
Investments—Equity Method and Joint Ventures; Derivatives and Hedging
In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. This ASU is effective for fiscal years beginning after December 15, 2020 (fiscal 2022). The adoption of this ASU is not expected to have any impact on the Business’s results of operations, cash flows or financial position.
Income taxes - simplifying the accounting for income taxes
In December 2019, the FASB issued ASU 2019-12: Simplifying the Accounting for Income Taxes (Topic 740), which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This ASU is effective for fiscal years beginning after December 15, 2020 (fiscal 2022), and interim periods within those fiscal years, with early adoption permitted. The Business is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Business's disclosures.
Investments - equity securities
In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825). This extensive ASU provides clarifications for three topics related to financial instruments accounting, some of which apply to the Business. For example, this ASU clarifies the disclosure requirements that apply to equity securities without a readily determinable fair value for which the measurement alternative is elected. This ASU is effective for fiscal years beginning after December 15, 2019 (fiscal 2021). The adoption of this ASU is not expected to have a material impact on the Business's results of operations, cash flows or financial position.
Compensation – retirement benefits – defined benefit plans
In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement benefits (Topic 715-20). This ASU amends ASC 715 to add, remove and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The ASU eliminates the requirement to disclose the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year. The ASU also removes the disclosure requirements for the effects of a one-percentage- point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost and the benefit obligation for postretirement health care benefits. This ASU is effective for fiscal years ending after December 15, 2020 (fiscal 2022) and must be applied on a retrospective basis. The Business is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Business's disclosures.
Financial instruments - credit losses
In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326), which amends the Board’s guidance on the impairment of financial instruments. The ASU adds to U.S. GAAP an impairment model that is based on expected losses rather than incurred losses, which is known as the current expected credit loss (“CECL”) model. The CECL model applies to most debt instruments (other than those measured at fair value), trade and other receivables, financial guarantee contracts, and loan commitments. The Business plans to adopt this ASU for fiscal years beginning after December 15, 2020 (fiscal 2022), including interim periods within those fiscal years. The Business is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Business’s financial position or results of operations.
Note 3. Exit and disposal activities
Transformational Cost Management Program
On December 20, 2018, WBA announced a transformational cost management program that is currently expected to deliver in excess of $2 billion of annual cost savings by fiscal 2022 for WBA (the “Transformational Cost Management Program”). The Transformational Cost Management Program, which is multi- faceted and includes optimization initiatives, global smart spending, global smart organization and the transformation of the information technology (IT) capabilities, is designed to help WBA achieve increased cost efficiencies.
- 13 -
Since the inception of the Transformational Cost Management Program to August 31, 2020, the Business has recognized cumulative pre-tax charges to net income of $211 million, which were primarily recorded within selling, general and administrative expenses. These charges included $116 million in asset impairments and $95 million in employee severance, business transition and other exit costs.
Costs related to exit and disposal activities under the Transformational Cost Management Program, which were recorded in selling, general and administrative expenses in the fiscal years ended August 31, 2020 and 2019, are as follows (in millions):
| 2020 | 2019 | |||||||
| Asset impairment1 | $ | 19 | $ | 97 | ||||
| Employee severance, business transition and other costs | 42 | 53 | ||||||
| Total pre-tax exit and disposal charges | $ | 61 | $ | 150 | ||||
1 Primarily includes write down of certain software.
The changes in liabilities and assets related to the exit and disposal activities under Transformational Cost Management Program include the following (in millions):
| Employee | ||||||||||||
| severance, | ||||||||||||
| business | ||||||||||||
| transition and | Asset | |||||||||||
| other costs | impairment | Total | ||||||||||
| Balance at August 31, 2018 | $ | — | $ | — | $ | — | ||||||
| Costs | 53 | 97 | 150 | |||||||||
| Payments | (23 | ) | — | (23 | ) | |||||||
| Other – non-cash | — | (97 | ) | (97 | ) | |||||||
| Currency translation adjustments | 1 | — | 1 | |||||||||
| Balance at August 31, 2019 | $ | 31 | $ | — | $ | 31 | ||||||
| Costs | 42 | 19 | 61 | |||||||||
| Payments | (15 | ) | — | (15 | ) | |||||||
| Other – non-cash | — | (19 | ) | (19 | ) | |||||||
| Currency translation adjustments | 2 | — | 2 | |||||||||
| Balance at August 31, 2020 | $ | 60 | $ | — | $ | 60 | ||||||
Note 4. Leases
The Business leases certain warehouses, distribution centers, office space, land, retail stores and equipment. Lease may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Business becomes legally obligated to make rent payments or the date the Business has the right to control the property. The Business recognizes operating lease rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales. See Note 2, summary of major accounting policies for additional information.
- 14 -
Supplemental balance sheet information related to leases were as follows (in millions):
| August 31, | ||||
| 2020 | ||||
| Operating leases: | ||||
| Operating lease right-of-use assets | $ | 271 | ||
| Operating lease obligations – current | $ | 68 | ||
| Operating lease obligations – non current | 209 | |||
| Total operating lease obligations | $ | 277 | ||
Total finance lease obligations as of August 31, 2020 were $10 million.
Supplemental income statement information related to leases were as follows (in millions):
| August 31, | ||||
| 2020 | ||||
| Operating lease cost | ||||
| Fixed | $ | 80 | ||
| Variable1 | 9 | |||
1 Includes real estate property taxes, common area maintenance and insurance
Other supplemental information was as follows (in millions):
| August 31, | ||||
| 2020 | ||||
| Cash paid for amounts included in the measurement of lease obligations | ||||
| Operating cash flows from operating leases | $ | 64 | ||
| Right-of-use assets obtained in exchange for new lease obligations: | ||||
| Operating leases | $ | 51 | ||
Average lease term and discount rate as of August 31, 2020 were as follows (in millions):
| August 31, | ||||
| 2020 | ||||
| Weighted average remaining lease term in years: | ||||
| Operating leases | 6.9 | |||
| Weighted average discount rate | ||||
| Operating leases | 3.42 | % | ||
- 15 -
The following table is a summary of the future minimum lease payments as of August 31, 2020 (in millions):
| Operating | ||||
| lease | ||||
| 2021 | $ | 80 | ||
| 2022 | 64 | |||
| 2023 | 44 | |||
| 2024 | 35 | |||
| 2025 | 27 | |||
| Later | 73 | |||
| Total undiscounted minimum lease payments | $ | 323 | ||
| Less: Present value discount | (46 | ) | ||
| Lease liability | $ | 277 | ||
Comparative disclosures prior to the adoption of ASC 842 Leases
Rental expense prior to the adoption of ASC 842 Leases, which includes common area maintenance, insurance and taxes, where appropriate, was as follows (in millions):
| 2019 | ||||
| Minimum rentals | $ | 69 | ||
| Contingent rentals | 7 | |||
| $ | 76 | |||
Note 5. Equity method investments
Summarized financial information for the Business’s equity method investments in aggregate is as follows (in millions):
| Balance sheets | 2020 | 2019 | ||||||
| Current assets | $ | 870 | $ | 908 | ||||
| Non-current assets | 169 | 159 | ||||||
| Current liabilities | 745 | 778 | ||||||
| Non-current liabilities | 27 | 32 | ||||||
| Shareholders’ equity | 267 | 257 | ||||||
| Statement of earnings | 2020 | 2019 | ||||||
| Sales | $ | 1,680 | $ | 1,696 | ||||
| Gross profit | 189 | 213 | ||||||
| Net earnings | 23 | 40 | ||||||
| Share of earnings from equity method investments | 10 | 15 | ||||||
The summarized financial information for equity method investments has been included on an aggregated basis for all investments as reported at the end of each fiscal year end.
Note 6. Goodwill and other intangible assets
Goodwill and indefinite-lived intangible assets are evaluated for impairment annually during the fourth quarter or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit or intangible asset below its carrying value. Based on the annual impairment evaluation completed as of June 1, 2020 valuation date, the fair value of the Business’s reporting units exceeded the carrying amounts.
As part of the Business’s impairment analysis, fair value of a reporting unit is determined using both the income and market approaches. The income approach requires management to estimate a number of factors for each reporting unit, including the projected future operating results, economic projections, anticipated future cash flows and discount rates considering the impact of COVID-19, among other potential impacts. The market approach estimates fair value using comparable marketplace fair value data from within a comparable industry grouping.
- 16 -
The determination of the fair value of the reporting units requires the Business to make significant estimates and assumptions including the business and financial performance of the Business’s reporting units, as well as how such performance may be impacted by COVID-19. These estimates and assumptions primarily include, but are not limited to: the selection of appropriate peer group companies, control premiums appropriate for acquisitions in the industries in which we compete, discount rates, terminal growth rates, and forecasts of revenue, operating income, depreciation, amortization and capital expenditures, including considering the impact of COVID-19.
Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized and the asset is written down to its estimated fair value. Indefinite-lived intangible assets’ fair values are estimated using the relief from royalty method of the income approach. The determination of the fair value of the indefinite-lived intangibles requires the Business to make significant estimates and assumptions. These estimates and assumptions primarily include, but are not limited to: forecasts of revenue, the selection of appropriate royalty rate and discount rates.
Although the Business believes its estimates of fair value are reasonable, actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions, including the impact of COVID-19, could have a significant impact on either the fair value of the reporting units and indefinite-lived intangibles, the amount of any goodwill and indefinite-lived intangible impairment charges, or both. These estimates can be affected by a number of factors including, but not limited to, the impact of COVID-19, its severity, duration and its impact on global economies, general economic conditions as well as our profitability. The Business will continue to monitor these potential impacts, including the impact of COVID-19 and economic, industry and market trends and the impact these may have on the Business.
Definite-lived intangible assets are evaluated for impairment whenever events or circumstances indicate that a certain asset or asset group may be impaired.
Changes in the carrying amount of goodwill are presented below (in millions):
| Carrying amount | ||||
| of goodwill | ||||
| August 31, 2018 | $ | 3,217 | ||
| Cumulative translation adjustments | (182 | ) | ||
| August 31, 2019 | $ | 3,035 | ||
| Cumulative translation adjustments | 239 | |||
| August 31, 2020 | $ | 3,274 | ||
- 17 -
The carrying amount and accumulated amortization of intangible assets consists of the following (in millions):
| August 31, 2020 | August 31, 2019 | |||||||
| Gross amortizable intangible assets | ||||||||
| Customer relationships | $ | 886 | $ | 828 | ||||
| Trade names, trademarks and other | 63 | 68 | ||||||
| Total gross amortizable intangible assets | 949 | 896 | ||||||
| Accumulated amortization | ||||||||
| Customer relationships | $ | 422 | $ | 326 | ||||
| Trade names, trademarks and other | 31 | 28 | ||||||
| Total accumulated amortization | 453 | 354 | ||||||
| Total amortizable intangible assets, net | $ | 496 | $ | 542 | ||||
| Indefinite-lived intangible assets (Tradenames and Trademarks) | $ | 185 | $ | 170 | ||||
| Total intangible assets, net | $ | 681 | $ | 712 | ||||
Amortization expense for intangible assets was $77 million and $78 million in fiscal 2020 and 2019, respectively. Estimated future annual amortization expense for the next five fiscal years for intangible assets recorded at August 31, 2019 is as follows (in millions):
| 2021 | 2023 | 2023 | 2024 | 2025 | ||||||||||||||||
| Estimated annual amortization expense | $ | 80 | $ | 80 | $ | 79 | $ | 78 | $ | 75 | ||||||||||
Note 7. Debt
Short-term debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. The carrying values of short-term debt approximated their respective fair values due to their short-term nature.
Interest paid on short-term debt was $37 million in fiscal 2020 and $63 million in fiscal 2019.
Note 8. Commitments and contingencies
The Business is involved in legal proceedings, including litigation, investigations, inspections, claims, inquiries and similar actions by pharmacy, healthcare, tax and other governmental authorities, arising in the normal course of the business. Legal proceedings, in general, can be expensive and disruptive. Some of these claims may purport to be or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Business is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters.
Like other companies in the retail pharmacy and pharmaceutical wholesale industries, the Business is subject to extensive regulation by national, state and local government agencies of countries in which it operates. There continues to be a heightened level of review and/or audit by regulatory authorities of, and increased litigation regarding, the Business’s and the rest of the health care and related industry’s business, compliance and reporting practices. As a result, the Business may regularly be the subject of government actions of the types described above.
The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome. With respect to litigation and other legal proceedings where the Business has determined that a loss is reasonably possible, the Business is unable to estimate the amount or range of reasonably possible loss due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Business believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Business’s Combined financial position. However, substantial unanticipated judgments, fines and rulings do sometimes occur. As a result, the Business could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid. In addition, as a result of governmental investigations or proceedings, the Business may be subject to damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs.
- 18 -
On 25 July 2019, the Competition and Markets Authority (“CMA”) issued a Statement of Objections against the Business which provisionally considers that the Business entered into arrangements to buy Nitrofurantoin from two suppliers and that these arrangements prevented or restricted competition. It is not a finding of infringement nor does it necessarily lead to an infringement decision. The Business takes UK competition law very seriously and does not believe that UK competition law has been infringed. The Business has reviewed the CMA's provisional position, as specified in its Statement of Objections, and responded in detail to the allegations. The Business continues to defend its position whilst working constructively with the CMA. The CMA’s final decision on the case outcome is expected in Spring 2021 and it is possible that the CMA may impose a financial penalty on the Business if it determines that competition law has in fact been infringed. Any penalty will be determined in accordance with applicable provisions of competition law.
Gain contingencies, if any, are recognized when they are realized.
Note 9. Income taxes
See Note 1 - Summary of major accounting policies for the Business’s carve-out methodology on Income taxes. The components of earnings before income tax provision were (in millions):
| 2020 | 2019 | |||||||
| Domestic | $ | 3 | $ | (26 | ) | |||
| Foreign | 265 | 157 | ||||||
| Total earnings before income tax provision | $ | 268 | $ | 131 | ||||
The income tax provision consists of the following (in millions):
| 2020 | 2019 | |||||||
| Current tax provision | ||||||||
| Domestic | $ | 5 | $ | (4 | ) | |||
| Foreign | 77 | 68 | ||||||
| Total current tax provision | 82 | 64 | ||||||
| Deferred tax provision | ||||||||
| Domestic | (5 | ) | (2 | ) | ||||
| Foreign | (6 | ) | (20 | ) | ||||
| Total deferred tax provision | (11 | ) | (22 | ) | ||||
| Total income tax provision | $ | 71 | $ | 42 | ||||
The difference between the Netherlands statutory income tax rate and the effective income tax rate is as follows:
| 2020 | 2019 | |||||||
| Statutory income tax rate | 25.0 | % | 25.0 | % | ||||
| Foreign income taxed at different rates | (7.1 | ) | (14.0 | ) | ||||
| Nondeductible expenses | 1.3 | 12.7 | ||||||
| Change in valuation allowance | 2.4 | 7.7 | ||||||
| Other items | 4.9 | 0.5 | ||||||
| Effective income tax rate | 26.5 | % | 31.9 | % | ||||
- 19 -
The net deferred tax liabilities included in the Combined Balance Sheets consist of the following (in millions):
| 2020 | 2019 | |||||||
| Deferred tax assets: | ||||||||
| Compensation and benefits | 11 | 11 | ||||||
| Tax attributes | 115 | 114 | ||||||
| Interest expense carryforward | 13 | 11 | ||||||
| Other deferred tax assets | 31 | 19 | ||||||
| Deferred tax assets | 170 | 155 | ||||||
| Less: valuation allowance | (118 | ) | (112 | ) | ||||
| Total deferred tax assets | 52 | 43 | ||||||
| Deferred tax liabilities: | ||||||||
| Accelerated depreciation | (35 | ) | (34 | ) | ||||
| Intangible assets | (137 | ) | (131 | ) | ||||
| Other deferred tax liabilities | (8 | ) | (8 | ) | ||||
| Total deferred tax liabilities | (180 | ) | (173 | ) | ||||
| Net deferred tax liabilities | $ | (128 | ) | $ | (130 | ) | ||
As of August 31, 2020 and 2019, the Business reported $3 million of total deferred tax assets within Other non-current assets on the Combined Balance Sheets.
As of August 31, 2020, the Business has recorded deferred tax assets for tax attributes of $115 million, primarily reflecting the benefit of $356 million in foreign ordinary losses that have an indefinite carryforward period and $ 95 million in foreign ordinary losses that will expire after 2036. The Business believes it is more-likely-than-not that the tax benefit from certain deferred tax assets will not be realized and has recorded a valuation allowance of $118 million against those deferred tax assets as of August 31, 2020.
Income taxes paid, net of refunds, was $101 million and $82 million for fiscal years 2020 and 2019, respectively.
ASC 740 provides guidance regarding the recognition, measurement, presentation and disclosure in the financial statement of tax positions taken or expected to be taken on a tax return, including the decision whether to file in a particular jurisdiction. As of August 31, 2020 and August 31, 2019, unrecognized tax benefits of $ 1 million and $1 million were reported as long-term liabilities on the Combined Balance Sheets while an immaterial amount is reported as current tax liabilities. Both of these amounts include interest and penalties, when applicable. The Business recognizes interest and penalties in the income tax provision in its Combined Statements of Earnings but not significant at August 31, 2020 and 2019.
As of August 31, 2020 and August 31, 2019, no unrecognized tax benefits would favorably impact the effective tax rate if recognized. Based on current knowledge, it is reasonably possible that no unrecognized tax benefits could decrease in the next twelve months due to anticipated tax audit settlements and the expirations of statutes of limitations associated with tax positions related to multiple tax jurisdictions. The Business files income tax returns in the Netherlands and multiple foreign jurisdictions and is generally no longer subject to income tax examinations prior to fiscal 2009.
As of August 31, 2020, the Business remains indefinitely reinvested with respect to outside basis differences in jurisdictions outside of the Parent company. It is not practicable to determine the amount of the unrecognized deferred tax liability it has with respect to temporary differences related to investments in foreign entities and foreign corporate joint ventures that are essentially permanent in duration.
Note 10. Retirement benefits
The Business sponsors several retirement plans, including defined benefit plans and defined contribution plans.
Defined benefit pension plans
The Business has unfunded defined benefit pension plans in Turkey and France. The total of net periodic pension cost for the year ended August 31, 2020 and August 31, 2019 is $4 million and $ 2 million, respectively. The defined benefit obligations for the pension plans aggregate $44 million and $39 million for the year ended August 31, 2020 and August 31, 2019, respectively.
- 20 -
Estimated annual future benefit payments for the next 10 years from defined benefit pension plans to participants are $1 million to $3 million. Based on current actuarial estimates, the Business plans to make contributions of $2 million to its defined benefit pension plans in fiscal 2021 and expects to make contributions beyond 2021, which will vary based upon many factors.
Defined contribution plans
The Business has defined contribution arrangements for current employees. The largest scheme is the UK’s Alliance Healthcare Retirement Savings Plan, to which both the Business and participating employees contribute. The cost recognized in the Combined Statement of Earnings was $28 million in fiscal 2020 and $23 million in fiscal 2019.
Note 11. Accumulated other comprehensive income (loss)
The following is a summary of net changes in accumulated other comprehensive income by component, net of tax (in millions):
| Pension/ | ||||||||||||
| post- | Cumulative | |||||||||||
| retirement | translation | |||||||||||
| obligations | adjustments | Total | ||||||||||
| Balance at August 31, 2018 | $ | 1 | $ | (1,094 | ) | $ | (1,093 | ) | ||||
| Other comprehensive loss | (7 | ) | (235 | ) | (242 | ) | ||||||
| Tax benefit / (provision) | 2 | — | 2 | |||||||||
| Net change in other comprehensive income (loss) | (5 | ) | (235 | ) | (240 | ) | ||||||
| Balance at August 31, 2019 | $ | (4 | ) | $ | (1,329 | ) | $ | (1,333 | ) | |||
| Other comprehensive income (loss) | (4 | ) | 314 | 310 | ||||||||
| Tax benefit / (provision) | 1 | — | 1 | |||||||||
| Net change in other comprehensive income (loss) | (3 | ) | 314 | 311 | ||||||||
| Balance at August 31, 2020 | $ | (7 | ) | $ | (1,015 | ) | $ | (1,022 | ) | |||
Note 12. Related parties
The Business, as part of its operations, has related party transactions and outstanding balances with Parent, WBA.
Corporate costs allocations
The Business’s Combined Financial Statements include allocation of corporate costs incurred by WBA, for services that are provided to or on behalf of the Business, using consistent and reasonable method based on gross profit metric. However, the expenses reflected in the Combined Financial Statements may not be indicative of the actual expenses that would have been incurred during the periods presented if the Business historically operated as a separate, stand-alone entity.
Allocated corporate costs included in Selling, general and administrative expense were for shared services and infrastructure provided, which includes costs such as information technology, accounting, legal, risk and insurance services, treasury, shareholder services and other corporate and infrastructure services. The Combined Statements of Earnings includes allocations of WBA’s general corporate costs of $31 million and $ 10 million for fiscal 2020 and 2019, respectively. All allocated corporate costs have been deemed paid by the Business to WBA in the period in which the cost was recognized in the Combined Statements of Income. These costs are included as cash outflow from the operating activities.
Sales to and purchases from Parent
The Business sold products to WBA of $1,779 million and $1,813 million in 2020 and 2019, respectively. The Business purchased products from WBA aggregating $166 million and $125 million in 2020 and 2019, respectively.
- 21 -
Related party balances
The amounts due to and from Parent, WBA and affiliates are as follows (in millions):
–Current assets
| 2020 | 2019 | |||||||
| Trade accounts receivable | $ | 255 | $ | 276 | ||||
| Debt due from Parent 1 | 1,302 | 1,143 | ||||||
| Total due from Parent | $ | 1,557 | $ | 1,419 | ||||
–Current liabilities
| 2020 | 2019 | |||||||
| Trade accounts payable | $ | 50 | 30 | |||||
| Debt due to Parent 2 | 8 | 9 | ||||||
| Other | 2 | 7 | ||||||
| Total due to Parent | $ | 60 | $ | 46 | ||||
–Noncurrent liabilities
| 2020 | 2019 | |||||||
| Due to Parent – Other | $ | 864 | $ | 801 | ||||
| 1 | Debt due from Parent includes cash pool receivables from Parent classified as investing activities in the Combined Statements of Cash Flows. |
| 2 | Debt due to Parent includes interest bearing debt. Total interest expense payable to Parent, recognized in the Combined Statement of Earnings was $34 million in fiscal 2020 and $31 million in fiscal 2019. |
- 22 -
Exhibit 99.2
WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
UNAUDITED COMBINED CONDENSED
BALANCE SHEETS
(in millions)
| November 30, 2020 | August 31, 2020 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 151 | $ | 143 | ||||
| Accounts receivable, net | 3,337 | 3,022 | ||||||
| Due from Parent (see Note 10) | 1,462 | 1,557 | ||||||
| Inventories | 1,701 | 1,535 | ||||||
| Other current assets | 306 | 376 | ||||||
| Total current assets | 6,957 | 6,633 | ||||||
| Non-current assets: | ||||||||
| Property, plant and equipment, net | 547 | 546 | ||||||
| Operating lease right-of-use asset | 278 | 271 | ||||||
| Goodwill | 3,282 | 3,274 | ||||||
| Intangible assets, net | 661 | 681 | ||||||
| Equity method investments | 142 | 134 | ||||||
| Other non-current assets | 84 | 97 | ||||||
| Total non-current assets | 4,994 | 5,003 | ||||||
| Total assets | $ | 11,951 | $ | 11,636 | ||||
| Liabilities and equity | ||||||||
| Current liabilities: | ||||||||
| Short-term debt | $ | 375 | $ | 368 | ||||
| Due to Parent (see Note 10) | 72 | 60 | ||||||
| Trade accounts payable | 4,642 | 4,313 | ||||||
| Operating lease obligation | 82 | 68 | ||||||
| Accrued expenses and other liabilities | 603 | 679 | ||||||
| Income taxes | 19 | 17 | ||||||
| Total current liabilities | 5,793 | 5,505 | ||||||
| Non-current liabilities: | ||||||||
| Operating lease obligation | 199 | 209 | ||||||
| Due to Parent (see Note 10) | 835 | 864 | ||||||
| Deferred income taxes | 130 | 131 | ||||||
| Other non-current liabilities | 71 | 73 | ||||||
| Total non-current liabilities | 1,235 | 1,277 | ||||||
| Commitments and contingencies (see Note 6) | ||||||||
| Equity: | ||||||||
| Net Parent investment | 5,878 | 5,814 | ||||||
| Accumulated other comprehensive loss | (1,019 | ) | (1,022 | ) | ||||
| Total equity attributable to the Business | 4,859 | 4,792 | ||||||
| Noncontrolling interests | 64 | 62 | ||||||
| Total equity | 4,923 | 4,854 | ||||||
| Total liabilities and equity | $ | 11,951 | $ | 11,636 | ||||
The accompanying notes to Combined Condensed Financial Statements are an integral part of these Statements.
- 1 -
WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
UNAUDITED COMBINED CONDENSED
STATEMENTS OF EQUITY
(in millions)
| Three months ended November 30, 2020 | ||||||||||||||||
| Equity attributable to | ||||||||||||||||
| the Business | ||||||||||||||||
| Accumulated | ||||||||||||||||
| other | ||||||||||||||||
| Net Parent | comprehensive | Noncontrolling | Total | |||||||||||||
| investment | income (loss) | interests | Equity | |||||||||||||
| August 31, 2020 | $ | 5,814 | $ | (1,022 | ) | $ | 62 | $ | 4,854 | |||||||
| Net earnings | 59 | — | 4 | 63 | ||||||||||||
| Other comprehensive income (loss), net of tax | — | 4 | — | 4 | ||||||||||||
| Adoption of new accounting standards | (3 | ) | — | (3 | ) | (5 | ) | |||||||||
| Net transfers to Parent | 8 | — | — | 8 | ||||||||||||
| November 30, 2020 | 5,878 | (1,019 | ) | 64 | 4,923 | |||||||||||
| Three months ended November 30, 2019 | ||||||||||||||||
| Equity attributable to | ||||||||||||||||
| the Business | ||||||||||||||||
| Accumulated | ||||||||||||||||
| other | ||||||||||||||||
| Net Parent | comprehensive | Noncontrolling | Total | |||||||||||||
| investment | income (loss) | interests | Equity | |||||||||||||
| August 31, 2019 | 5,848 | (1,333 | ) | 58 | 4,573 | |||||||||||
| Net earnings | 58 | — | 3 | 61 | ||||||||||||
| Other comprehensive income (loss), net of tax | — | 175 | 1 | 176 | ||||||||||||
| Net transfers to Parent | (3 | ) | — | — | (3 | ) | ||||||||||
| November 30, 2019 | $ | 5,903 | $ | (1,158 | ) | $ | 62 | $ | 4,806 | |||||||
The accompanying notes to Combined Condensed Financial Statements are an integral part of these Statements.
- 2 -
WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
UNAUDITED COMBINED CONDENSED
STATEMENTS OF EARNINGS
(in millions)
| Three months ended November 30, | ||||||||
| 2020 | 2019 | |||||||
| Sales | $ | 4,793 | $ | 4,359 | ||||
| Related party sales (see Note 10) | 453 | 457 | ||||||
| Total Sales | 5,246 | 4,816 | ||||||
| Cost of sales | 4,737 | 4,331 | ||||||
| Gross profit | 509 | 486 | ||||||
| Selling, general and administrative expenses | 423 | 399 | ||||||
| Operating income | 87 | 87 | ||||||
| Other income (expense) | — | — | ||||||
| Earnings before interest and income tax provision | 87 | 87 | ||||||
| Interest expense, net | 11 | 13 | ||||||
| Earnings before income tax provision | 76 | 74 | ||||||
| Income tax provision | 20 | 17 | ||||||
| Post tax earnings from equity method investments | 7 | 4 | ||||||
| Net earnings | 63 | 61 | ||||||
| Net earnings attributable to noncontrolling interests | 4 | 3 | ||||||
| Net earnings attributable to the Business | $ | 59 | $ | 58 | ||||
The accompanying notes to Combined Condensed Financial Statements are an integral part of these Statements.
- 3 -
WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
UNAUDITED COMBINED CONDENSED
STATEMENTS OF COMPREHENSIVE INCOME
(in millions)
| Three months ended November 30, | ||||||||
| 2020 | 2019 | |||||||
| Comprehensive income: | ||||||||
| Net earnings | $ | 63 | $ | 61 | ||||
| Other comprehensive income, net of tax: | ||||||||
| Currency translation adjustments | 4 | 176 | ||||||
| Total other comprehensive income | 4 | 176 | ||||||
| Total comprehensive income | 67 | 237 | ||||||
| Comprehensive income attributable to noncontrolling interests | 5 | 4 | ||||||
| Comprehensive income attributable to the Business | $ | 62 | $ | 233 | ||||
The accompanying notes to Combined Condensed Financial Statements are an integral part of these Statements.
- 4 -
WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
UNAUDITED COMBINED CONDENSED
STATEMENTS OF CASH FLOWS
(in millions)
| Three months ended November 30, | ||||||||
| 2020 | 2019 | |||||||
| Cash flows from operating activities: | ||||||||
| Net earnings | $ | 63 | $ | 61 | ||||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 37 | 35 | ||||||
| Deferred income taxes | 1 | (2 | ) | |||||
| Earnings from equity method investments | (7 | ) | (4 | ) | ||||
| Other | 2 | 1 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | (335 | ) | (320 | ) | ||||
| Inventories | (171 | ) | (220 | ) | ||||
| Other current assets | 64 | (3 | ) | |||||
| Trade accounts payable | 336 | 395 | ||||||
| Accrued expenses and other liabilities | (75 | ) | (41 | ) | ||||
| Income taxes | 2 | (10 | ) | |||||
| Other non-current assets and liabilities | 13 | 1 | ||||||
| Accounts receivable from Parent, net | (2 | ) | 21 | |||||
| Net cash used for operating activities | (73 | ) | (86 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Additions to property, plant and equipment | (20 | ) | (14 | ) | ||||
| Net change in cash pool receivable from Parent | 82 | 133 | ||||||
| Net change in loan receivable from Parent | 29 | (1 | ) | |||||
| Net cash used for investing activities | 92 | 118 | ||||||
| Cash flows from financing activities: | ||||||||
| Net change in short-term debt with maturities of 3 months or less | 10 | (13 | ) | |||||
| Other | (2 | ) | (1 | ) | ||||
| Net distribution to Parent | (29 | ) | (1 | ) | ||||
| Net cash used for financing activities | (21 | ) | (15 | ) | ||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1 | 1 | ||||||
| Changes in cash, cash equivalents and restricted cash | ||||||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (1 | ) | 19 | |||||
| Cash, cash equivalents and restricted cash at beginning of period | 311 | 319 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 310 | $ | 338 | ||||
The accompanying notes to Combined Condensed Financial Statements are an integral part of these Statements.
- 5 -
WALGREENS BOOTS ALLIANCE
WHOLESALE AND RETAIL BUSINESSES
NOTES TO COMBINED CONDENSED FINANCIAL STATEMENTS (UNAUDITED)
Note 1. Organization, operations and basis of presentation
Organization
These Combined Condensed Financial Statements comprise certain pharmaceutical wholesale and retail pharmacy operations (the “Business”) of Walgreens Boots Alliance, Inc. (“WBA”).
Pharmaceutical wholesale operations comprise businesses located in the United Kingdom, France, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Sales within these businesses are principally derived from wholesaling and distribution of a comprehensive offering of brand name and generic pharmaceuticals, health and beauty products, home healthcare supplies and equipment and related services to pharmacies, doctors, health centers and hospitals.
Retail pharmacy operations comprise retail stores in Norway, the Netherlands and Lithuania. Sales within these businesses are principally derived from pharmacy led sales of prescription drugs and health and wellness, beauty and personal care and other consumer products.
On January 6, 2021, WBA entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with AmerisourceBergen. Pursuant to the terms and subject to the conditions set forth in the Share Purchase Agreement, AmerisourceBergen will purchase the Business for approximately $6.5 billion, comprised of $6.275 billion in cash, subject to certain purchase price adjustments, and 2 million shares of AmerisourceBergen common stock.
Basis of presentation
The Business’s Combined Condensed Financial Statements have been prepared on a stand-alone basis and reflect a combination of entities and portions of certain entities under common control that have been “carved out” of and derived from the WBA historical consolidated financial statements and accounting records. Accordingly, WBA’s net investment in this Business (“Net Parent Investment”) is presented in lieu of a controlling interest’s equity in the Combined Condensed Financial Statements. Therefore, the Combined Condensed Financial Statements reflect the Business’s historical combined financial position, results of operations and cash flows as the Business was historically operated as part of WBA. As a result, the Business’s Combined Condensed Financial Statements may not be indicative of the Business’s future performance and do not necessarily reflect what the Business’s Combined Condensed results of operations, financial condition and cash flows would have been had the Business operated as a separate Business during the periods presented.
The Business is comprised of certain stand-alone legal entities for which discrete financial information is available, as well as portions of legal entities for which discrete financial information is not available (shared legal entities). For the shared legal entities for which discrete financial information was not available, allocation methodologies were applied to certain accounts to allocate amounts to the Business as discussed further in Note 10 – Related parties. The Combined Condensed Statements of Earnings include all sales and costs directly attributable to the Business, including costs for facilities, functions and services used by the Business. Certain shared costs and benefits have been directly charged to the Business based on direct usage or other allocation methods.
The Business participates in certain shared cash pool arrangements with WBA but retains a legal right to cash balances swept by WBA. WBA funds the Business’s operating and investing activities as needed. This arrangement is not reflective of the manner in which the Business would have been able to finance its operations had it been a stand-alone business separate from WBA during the periods presented. Cash pooling arrangements along with transfers to and from WBA’s cash management accounts are reflected in the Combined Condensed Balance Sheets as current amounts Due to and Due from Parent, and in the Combined Condensed Statements of Cash Flows as net investing activities. These Due to and Due from Parent balances are expected to be settled in the ordinary course of business.
The Combined Condensed Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The Business uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All transactions between the entities comprising the Business have been eliminated. As described in Note 10 – Related parties, all significant transactions between the Business and WBA have been included in these Combined Condensed Financial Statements.
- 6 -
The combined operations of the Business are treated as if it was a separate taxpayer following the separate return methodology. See Note 7 – Income taxes.
The preparation of the Combined Condensed Financial Statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. These estimates are based on the information available at the time, historical experience and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of coronavirus COVID-19 ("COVID-19"). Significant estimates inherent in the preparation of these Combined Condensed Financial Statements include, but are not limited to, accounting for inventory, evaluation of goodwill and other assets for impairment, income taxes and other contingencies.
The impact of COVID-19 on the Business’s financial results depends on numerous evolving factors including, but not limited to, the severity and duration of COVID-19, and the potential impact to the customers, team members, suppliers, vendors, business partners, and distribution channels of the Business.
Management of the Business have evaluated subsequent events through January 29, 2021 which is the date of issuance or the date on which the financial statements were available to be issued.
The Combined Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Business believes that the disclosures are adequate to make the information presented not misleading. These unaudited Combined Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto for the fiscal year ended August 31, 2020. In the opinion of management, the unaudited Combined Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods.
Certain amounts in the Combined Condensed Financial Statements and associated notes may not foot due to rounding.
Note 2. Exit and disposal activities
Transformational Cost Management Program
On December 20, 2018, WBA announced a transformational cost management program that is currently expected to deliver in excess of $2 billion of annual cost savings by fiscal 2022 for WBA (the “Transformational Cost Management Program”). The Transformational Cost Management Program, which is multi- faceted and includes optimization initiatives, global smart spending, global smart organization and the transformation of the information technology (IT) capabilities, is designed to help WBA achieve increased cost efficiencies.
Since the inception of the Transformational Cost Management Program to November 30, 2020, the Business has recognized cumulative pre-tax charges to net income of $214 million, which were primarily recorded within selling, general and administrative expenses. These charges included $116 million in asset impairments and $98 million in employee severance, business transition and other exit costs.
Costs related to exit and disposal activities under the Transformational Cost Management Program, which were recorded in selling, general and administrative expenses in the fiscal years ended November 30, 2020 and 2019, are as follows (in millions):
| Three months ended November 30, | ||||||||
| 2020 | 2019 | |||||||
| Employee severance, business transition and other costs | 3 | 5 | ||||||
| Total pre-tax exit and disposal charges | $ | 3 | $ | 5 | ||||
- 7 -
The changes in liabilities related to the exit and disposal activities under Transformational Cost Management Program include the following (in millions):
| Employee severance, business transition and other costs | ||||
| Balance at August 31, 2020 | $ | 60 | ||
| Costs | 3 | |||
| Payments | (3 | ) | ||
| Balance at November 30, 2020 | $ | 60 |
Note 3. Leases
The Business leases certain warehouses, distribution centers, office space, land, retail stores and equipment. Lease may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Business becomes legally obligated to make rent payments or the date the Business has the right to control the property. The Business recognizes operating lease rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.
Finance lease obligations as of November 30, 2020 and August 31, 2020 was $9 million and $10 million respectively.
Supplemental balance sheet information related to leases were as follows (in millions):
| November 30, 2020 | August 31, 2020 | |||||||
| Operating leases: | ||||||||
| Operating lease right-of-use assets | $ | 278 | $ | 271 | ||||
| Operating lease obligations – current | 82 | 68 | ||||||
| Operating lease obligations – non-current | 199 | 209 | ||||||
| Total operating lease obligations | $ | 281 | $ | 277 | ||||
Supplemental income statement information related to leases were as follows (in millions):
| Three months ended November 30, | ||||||||
| 2020 | 2019 | |||||||
| Operating lease cost | ||||||||
| Fixed | $ | 21 | $ | 19 | ||||
| Variable1 | 2 | 4 | ||||||
1 Includes real estate property taxes, common area maintenance and insurance
Other supplemental information was as follows (in millions):
| Three months ended November 30, | ||||||||
| 2020 | 2019 | |||||||
| Cash paid for amounts included in the measurement of lease obligations | ||||||||
| Operating cash flows from operating leases | $ | 15 | $ | 9 | ||||
| Right-of-use assets obtained in exchange for new lease obligations: | ||||||||
| Operating leases | 19 | 6 | ||||||
- 8 -
Average lease term and discount rate as of November 30, 2020 and August 31, 2020 were as follows (in millions):
| Weighted average terms and discount rates: | November 30, 2020 | August 31, 2020 | ||||||
| Weighted average remaining lease term in years: | ||||||||
| Operating leases | 6.9 | 6.9 | ||||||
| Weighted average discount rate | ||||||||
| Operating leases | 3.47 | % | 3.42 | % | ||||
The following table is a summary of the future minimum lease payments as of November 30, 2020 (in millions):
Future lease payments:
| Fiscal year | Operating lease | |||
| 2021(Remaining period) | $ | 58 | ||
| 2022 | 63 | |||
| 2023 | 47 | |||
| 2024 | 38 | |||
| 2025 | 30 | |||
| 2026 | 19 | |||
| Later | 57 | |||
| Total undiscounted minimum lease payments | $ | 312 | ||
| Less: Present value discount | (31 | ) | ||
| Lease liability | $ | 281 |
Note 4. Goodwill and other intangible assets
Goodwill and indefinite-lived intangible assets are evaluated for impairment annually during the fourth quarter or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit or intangible asset below its carrying value. Based on the annual impairment evaluation completed as of June 1, 2020 valuation date, the fair value of the Business’s reporting units exceeded the carrying amounts.
The determination of the fair value of the reporting units requires the Business to make significant estimates and assumptions including the business and financial performance of the Business’s reporting units, as well as how such performance may be impacted by COVID-19.
Although the Business believes its estimates of fair value are reasonable, actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions, including the impact of COVID-19, could have a significant impact on either the fair value of the reporting units and indefinite-lived intangibles, the amount of any goodwill and indefinite-lived intangible impairment charges, or both. These estimates can be affected by a number of factors including, but not limited to, the impact of COVID-19, its severity, duration and its impact on global economies, general economic conditions as well as our profitability. The Business will continue to monitor these potential impacts, including the impact of COVID-19 and economic, industry and market trends and the impact these may have on the Business.
Changes in the carrying amount of goodwill are presented below (in millions):
| Carrying amount | ||||
| of goodwill | ||||
| August 31, 2020 | $ | 3,274 | ||
| Cumulative translation adjustments | 9 | |||
| November 30, 2020 | $ | 3,282 | ||
- 9 -
The carrying amount and accumulated amortization of intangible assets consists of the following (in millions):
| November 30, 2020 | August 31, 2020 | |||||||
| Gross amortizable intangible assets | ||||||||
| Customer relationships | $ | 888 | $ | 886 | ||||
| Trade names, trademarks and other | 63 | 63 | ||||||
| Total gross amortizable intangible assets | 951 | 949 | ||||||
| Accumulated amortization | ||||||||
| Customer relationships | $ | 443 | $ | 422 | ||||
| Trade names, trademarks and other | 33 | 31 | ||||||
| Total accumulated amortization | 476 | 453 | ||||||
| Total amortizable intangible assets, net | $ | 475 | $ | 496 | ||||
| Indefinite-lived intangible assets (Tradenames and Trademarks) | $ | 186 | $ | 185 | ||||
| Total intangible assets, net | $ | 661 | $ | 681 | ||||
Amortization expense for intangible assets was $21 million and $19 million for the three months ended November 2020 and 2019, respectively. Estimated future annual amortization expense for the next five fiscal years for intangible assets recorded at November 30, 2020 is as follows (in millions):
| 2022 | 2023 | 2024 | 2025 | 2026 | ||||||||||||||||
| Estimated annual amortization expense | $ | 79 | $ | 79 | $ | 79 | $ | 78 | $ | 74 | ||||||||||
Note 5. Debt
Short-term debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. The carrying values of short-term debt approximated their respective fair values due to their short-term nature.
Interest paid on short-term debt was $9 million and $10 million for the three months ended November 30, 2020 and 2019, respectively.
Note 6. Commitments and contingencies
The Business is involved in legal proceedings, including litigation, investigations, inspections, claims, inquiries and similar actions by pharmacy, healthcare, tax and other governmental authorities, arising in the normal course of the business. Legal proceedings, in general, can be expensive and disruptive. Some of these claims may purport to be or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Business is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters.
Like other companies in the retail pharmacy and pharmaceutical wholesale industries, the Business is subject to extensive regulation by national, state and local government agencies of countries in which it operates. There continues to be a heightened level of review and/or audit by regulatory authorities of, and increased litigation regarding, the Business’s and the rest of the health care and related industry’s business, compliance and reporting practices. As a result, the Business may regularly be the subject of government actions of the types described above.
The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome. With respect to litigation and other legal proceedings where the Business has determined that a loss is reasonably possible, the Business is unable to estimate the amount or range of reasonably possible loss due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Business believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Business’s Combined Condensed financial position. However, substantial unanticipated judgments, fines and rulings do sometimes occur. As a result, the Business could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid. In addition, as a result of governmental investigations or proceedings, the Business may be subject to damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs.
- 10 -
On July 25, 2019, the Competition and Markets Authority (“CMA”) issued a Statement of Objections against the Business which provisionally considers that the Business entered into arrangements to buy Nitrofurantoin from two suppliers and that these arrangements prevented or restricted competition. It is not a finding of infringement nor does it necessarily lead to an infringement decision. The Business takes UK competition law very seriously and does not believe that UK competition law has been infringed. The Business has reviewed the CMAs provisional position, as specified in its Statement of Objections, and responded in detail to the allegations. The Business continues to defend its position whilst working constructively with the CMA. The CMA’s final decision on the case outcome is expected in Spring 2021 and it is possible that the CMA may impose a financial penalty on the Business if it determines that competition law has in fact been infringed. Any penalty will be determined in accordance with applicable provisions of competition law.
Gain contingencies, if any, are recognized when they are realized.
Note 7. Income taxes
The effective tax rate for the three months ended November 30, 2020 was 26.38%, primarily due to earnings in various jurisdictions taxed at different statutory tax rates. The effective tax rate for the three months ended November 30, 2019 was 22.88%, primarily due to earnings in various jurisdictions taxed at different statutory tax rates.
Income taxes paid for the three months ended November 30, 2020 were $7 million, compared to $5 million for the three months ended November 30, 2019.
During the next twelve months, based on current knowledge, it is reasonably possible that no unrecognized tax benefits could decrease in the next twelve months due to anticipated tax audit settlements and the expirations of statutes of limitations associated with tax positions related to multiple tax jurisdictions..
Note 8. Retirement benefits
The Business sponsors several retirement plans, including defined benefit plans and defined contribution plans.
Defined benefit pension plans
The Business has unfunded defined benefit pension plans in Turkey and France. The total of net periodic pension cost for the three months ended November 30, 2020 and 2019 is $1 million.
The Business plans to make $2 million of expected contributions for the whole year to its defined benefit pension plans in fiscal 2021.
Defined contribution plans
The Business has defined contribution arrangements for current employees. The largest scheme is the UK’s Alliance Healthcare Retirement Savings Plan, to which both the Business and participating employees contribute. The cost recognized in the Combined Condensed Statement of Earnings was $9 million and $11 million for the three months ended November 30, 2020 and 2019, respectively.
- 11 -
Note 9. Accumulated other comprehensive income (loss)
The following is a summary of net changes in accumulated other comprehensive income by component, net of tax (in millions):
| Pension/ | ||||||||||||
| post- | Cumulative | |||||||||||
| retirement | translation | |||||||||||
| obligations | adjustments | Total | ||||||||||
| Balance at August 31, 2020 | $ | (7 | ) | $ | (1,015 | ) | $ | (1,022 | ) | |||
| Other comprehensive income | — | 4 | 4 | |||||||||
| Balance at November 30, 2020 | $ | (7 | ) | $ | (1,012 | ) | $ | (1,019 | ) | |||
| Pension/ | ||||||||||||
| post- | Cumulative | |||||||||||
| retirement | translation | |||||||||||
| obligations | adjustments | Total | ||||||||||
| Balance at August 31, 2019 | $ | (4 | ) | $ | (1,329 | ) | $ | (1,333 | ) | |||
| Other comprehensive income | — | 175 | 175 | |||||||||
| Balance at November 30, 2019 | $ | (4 | ) | $ | (1,154 | ) | $ | (1,158 | ) | |||
Note 10. Related parties
The Business, as part of its operations, has related party transactions and outstanding balances with Parent, WBA.
Corporate costs allocations
The Business’s Combined Condensed Financial Statements include allocation of corporate costs incurred by WBA, for services that are provided to or on behalf of the Business, using consistent and reasonable method based on gross profit metric. However, the expenses reflected in the Combined Condensed Financial Statements may not be indicative of the actual expenses that would have been incurred during the periods presented if the Business historically operated as a separate, stand-alone entity.
Allocated corporate costs included in Selling, general and administrative expense were for shared services and infrastructure provided, which includes costs such as information technology, accounting, legal, risk and insurance services, treasury, shareholder services and other corporate and infrastructure services. The Combined Condensed Statements of Earnings includes allocations of WBA’s general corporate costs of $5 million and $4 million for the three months ended November 30, 2020 and 2019, respectively. All allocated corporate costs have been deemed paid by the Business to WBA in the period in which the cost was recognized in the Combined Condensed Statements of Income. These costs are included as cash outflow from the operating activities.
Sales to and purchases from Parent
The Business sold products to WBA of $453 million and $457 million in the three months ended November 30, 2020 and 2019, respectively. The Business purchased products from WBA aggregating $36 million and $35 million in the three months ended November 30, 2020 and 2019, respectively.
Related party balances
The amounts due to and from Parent, WBA and affiliates are as follows (in millions):
–Current assets
| November 30, 2020 | August 31, 2020 | |||||||
| Trade accounts receivable | $ | 265 | $ | 255 | ||||
| Debt due from Parent 1 | 1,197 | 1,302 | ||||||
| Total due from Parent | $ | 1,462 | $ | 1,557 | ||||
- 12 -
–Current liabilities
| November 30, 2020 | August 31, 2020 | |||||||
| Trade accounts payable | $ | 53 | 50 | |||||
| Debt due to Parent 2 | 18 | 8 | ||||||
| Other | 1 | 2 | ||||||
| Total due to Parent | $ | 72 | $ | 60 | ||||
–Noncurrent liabilities
| November 30, 2020 | August 31, 2020 | |||||||
| Due to Parent – Other | $ | 835 | $ | 864 | ||||
| 1 | Debt due from Parent includes cash pool receivables from Parent classified as investing activities in the Combined Condensed Statements of Cash Flows. | |
| 2 | Debt due to Parent includes interest bearing debt. Total interest expense payable to Parent, recognized in the Combined Condensed Statement of Earnings was $8 million and $9 million in the three months ended November 30, 2020 and 2019, respectively. |
Note 11. New accounting pronouncements
Adoption of new accounting pronouncements
Financial Instruments
In March 2020, FASB issued ASU 2020-03. This ASU improves and clarifies various financial instruments topics. The ASU includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Business adopted the new standard effective September 1, 2020 and the adoption did not have any impact on the Business’s results of operations, cash flows or financial position.
Investments - equity securities
In April 2019, the Financial Accounting Standard Board ("FASB") issued Accounting Standards Update ("ASU") 2019-04, Codification Improvements to Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825). This extensive ASU provides clarifications for three topics related to financial instruments accounting, some of which apply to the Business. For example, this ASU clarifies the disclosure requirements that apply to equity securities without a readily determinable fair value for which the measurement alternative is elected. The Business adopted the new standard effective September 1, 2020 and the adoption did not have any impact on the Business’s results of operations, cash flows or financial position.
Compensation – retirement benefits – defined benefit plans
In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement benefits (Topic 715-20). This ASU amends ASC 715 to add, remove and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The ASU eliminates the requirement to disclose the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year. The ASU also removes the disclosure requirements for the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost and the benefit obligation for postretirement health care benefits. The Business adopted the new standard effective September 1, 2020 and the adoption did not have any impact on the Business’s results of operations, cash flows or financial position.
Financial instruments - credit losses
In June 2016, the FASB issued ASU 2016-13: Measurement of Credit Losses on Financial Instruments (Topic 326), which amends the Board’s guidance on the impairment of financial instruments. The ASU adds to U.S. GAAP an impairment model that is based on expected losses rather than incurred losses, which is known as the current expected credit loss ("CECL") model. The CECL model applies to most debt instruments (other than those measured at fair value), trade and other receivables, financial guarantee contracts, and loan commitments. The Business adopted the new standard effective September 1, 2020, using a modified retrospective transition method, which requires a cumulative- effect adjustment of $3 million to the opening balance of net parent investment to be recognized on the date of adoption with prior periods not restated. The adoption did not have a material impact on the Business’s financial position, cash flows or results of operations.
- 13 -
New accounting pronouncements not yet adopted
Codification Improvements – Disclosures
In October 2020, the FASB issued ASU 2020-10, Codification Improvements - Disclosures. This ASU improves consistency by amending the codification to include all disclosure guidance in the appropriate disclosure sections and clarifies application of various provisions in the Codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. This ASU is effective for fiscal years beginning after December 15, 2020 (fiscal 2022). This ASU will not affect the Businesss results of operations, cash flows or financial position. The Business does not expect to have a material impact on the disclosures to the financial statement of the Business.
Effects of Reference Rate Reform on Financial Reporting
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates ("IBORs") and, particularly, the risk of cessation of the London Interbank Offered Rate ("LIBOR"), regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. The ASU can be adopted no later than December 1, 2022 (fiscal year 2023) with early adoption permitted. The Business is evaluating the effect of adopting this new accounting guidance.
Investments - equity securities; Investments—Equity Method and Joint Ventures; Derivatives and Hedging
In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. This ASU is effective for fiscal years beginning after December 15, 2020 (fiscal 2022). The Business is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Businesss results of operations, cash flows or financial position.
Income taxes - simplifying the accounting for income taxes
In December 2019, the FASB issued ASU 2019-12: Simplifying the Accounting for Income Taxes (Topic 740), which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This ASU is effective for fiscal years beginning after December 15, 2020 (fiscal 2022), and interim periods within those fiscal years, with early adoption permitted. The Business is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Businesss disclosures.
Note 12. Supplemental Information
Accounts receivable
Accounts receivable are stated net of allowances for doubtful accounts. Accounts receivable balances primarily consist of trade receivables due from customers, including amounts due from third party providers (e.g., pharmacy benefit managers, insurance companies and governmental agencies), clients and members. Trade receivables were $3.2 billion and $2.9 billion at November 30, 2020 and August 31, 2020. Other accounts receivable balances consist primarily of receivables from vendors and manufacturers. The carrying values of trade accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.
In developing an estimate of the allowances for doubtful accounts, the Business considers historical information, current conditions and all reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The allowance for doubtful accounts for trade receivables at November 30, 2020 and August 31, 2020 was $41 million and $35 million, respectively.
Factoring arrangements
The Business entered into factoring agreements with various European financial institutions to sell accounts receivable under non-recourse agreements, transferring effective control and risk related to the receivables. These transactions are treated as a sale and were accounted for as a reduction in accounts receivable. The cost of factoring such accounts receivable, is reflected in the Combined Condensed Statement of Earnings within Selling, general and administrative expenses. The Business expects to continue to use this factoring arrangement periodically to assist with our general working capital requirements.
- 14 -
Depreciation and amortization
Depreciation and amortization expense for property, plant and equipment, including capitalized system development costs and software, was $16 million for the three months ended November 30, 2020 and 2019.
Accumulated depreciation and amortization on property, plant and equipment was $0.4 billion at November 30, 2020 and $0.3 billion at August 31, 2020.
Restricted cash
The Business is required to maintain certain cash deposits with banks mainly consisting of deposits restricted under contractual agency agreements and cash restricted by law and other obligations. At November 30, 2020 and August 31, 2020, the amount of such restricted cash was $159 million and $168 million, respectively, and is reported in other current assets on the Combined Condensed Balance Sheets.
The following represents a reconciliation of cash and cash equivalents in the Combined Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Combined Condensed Statements of Cash Flows as of November 30, 2020 and August 31, 2020 (in millions):
| November 30, 2020 | August 31, 2020 | |||||||
| Cash and cash equivalents | $ | 151 | $ | 143 | ||||
| Restricted cash (included in other current assets) | 159 | 168 | ||||||
| Cash, cash equivalents and restricted cash | $ | 310 | $ | 311 | ||||
- 15 -
Exhibit 99.3
Unaudited Condensed Combined Pro Forma Balance Sheet
As of December 31, 2020
(in millions)
AmerisourceBergen Corporation | Alliance Healthcare | Pro Forma Adjustments | Notes | Pro Forma Combined | ||||||||||||||
| Assets | ||||||||||||||||||
| Current Assets: | ||||||||||||||||||
| Cash and cash equivalents | $ | 4,891 | $ | 151 | $ | (3,417 | ) | (a) | $ | 1,625 | ||||||||
| Accounts receivable, net | 14,886 | 3,337 | - | 18,223 | ||||||||||||||
| Inventories | 13,179 | 1,701 | - | 14,880 | ||||||||||||||
| Right to recover asset | 1,192 | - | 1,192 | |||||||||||||||
| Income tax receivable | 317 | - | 317 | |||||||||||||||
| Prepaid expenses and other | 235 | 306 | - | 541 | ||||||||||||||
| Due from Walgreen Boots Alliance | - | 1,462 | (1,197 | ) | (b) | 265 | ||||||||||||
| Total current assets | 34,700 | 6,957 | (4,614 | ) | 37,043 | |||||||||||||
| Property and equipment, net | 1,477 | 547 | - | (c) | 2,024 | |||||||||||||
| Goodwill | 6,710 | 3,282 | 605 | (d) | 10,597 | |||||||||||||
| Other intangible assets | 1,862 | 661 | 1,550 | (e) | 4,073 | |||||||||||||
| Deferred income taxes | 327 | - | - | 327 | ||||||||||||||
| Other assets | 771 | 504 | - | 1,275 | ||||||||||||||
| Total Assets | $ | 45,847 | $ | 11,951 | $ | (2,459 | ) | $ | (55,339 | ) | ||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||
| Accounts payable | $ | 33,450 | $ | 4,642 | $ | - | $ | 38,092 | ||||||||||
| Accrued expenses and other | 1,535 | 704 | 100 | (f) | 2,339 | |||||||||||||
| Short-term debt | 59 | 375 | (375 | ) | (g) | 59 | ||||||||||||
| Due to Walgreen Boots Alliance | - | 72 | (19 | ) | (b) | 53 | ||||||||||||
| Total current liabilities | 35,044 | 5,793 | (294 | ) | 40,543 | |||||||||||||
| Long-term debt | 3,641 | - | 3,009 | (h) | 6,650 | |||||||||||||
| Accrued income taxes | 287 | - | - | 287 | ||||||||||||||
| Deferred income taxes | 704 | 130 | 456 | (i) | 1,290 | |||||||||||||
| Other liabilities | 483 | 270 | - | 753 | ||||||||||||||
| Accrued litigation liability | 6,199 | - | - | 6,199 | ||||||||||||||
| Due to Walgreen Boots Alliance | - | 835 | (835 | ) | (b) | - | ||||||||||||
| Stockholders' equity | ||||||||||||||||||
| Common stock | 3 | - | - | 3 | ||||||||||||||
| Additional paid-in capital | 5,188 | 5,878 | (5,650 | ) | (j) | 5,416 | ||||||||||||
| Retained earnings | 781 | - | (100 | ) | (f) | 681 | ||||||||||||
| Accumulated other comprehensive loss | (71 | ) | (1,019 | ) | 1,019 | (j) | (71 | ) | ||||||||||
| Treasury stock | (6,598 | ) | - | - | (6,598 | ) | ||||||||||||
| Total equity, including non-controlling interest | (697 | ) | 4,859 | (4,731 | ) | (569 | ) | |||||||||||
| Noncontrolling interest | 186 | 64 | (64 | ) | (j) | 186 | ||||||||||||
| Total (deficit) equity | (511 | ) | 4,923 | (4,795 | ) | (383 | ) | |||||||||||
| Total liabilities and stockholders' (deficit) equity | $ | 45,847 | $ | 11,951 | $ | (2,459 | ) | $ | (55,339 | ) | ||||||||
Unaudited Condensed Combined Pro Forma Statement of Operations
Fiscal Year Ended September 30, 2020
(in millions, except per share information)
AmerisourceBergen Corporation | Alliance Healthcare | Pro Forma Adjustments | Notes | Pro Forma Combined | ||||||||||||||
| Revenue | $ | 189,894 | $ | 19,069 | $ | - | $ | 208,963 | ||||||||||
| Cost of goods sold | 184,702 | 17,130 | - | 201,832 | ||||||||||||||
| Gross profit | 5,192 | 1,939 | - | 7,131 | ||||||||||||||
| Operating expenses: | ||||||||||||||||||
| Distribution, selling, and administrative | 2,767 | 1,479 | - | 4,246 | ||||||||||||||
| Depreciation and amortization | 391 | 141 | 100 | (e) | 632 | |||||||||||||
| Employee severance, litigation, and other | 6,807 | - | - | 6,807 | ||||||||||||||
| Impairment of PharMEDium assets | 362 | - | - | 362 | ||||||||||||||
| Operating (loss) income | (5,135 | ) | 319 | (100 | ) | (4,916 | ) | |||||||||||
| Other (income) loss | (2 | ) | 2 | (14 | ) | (k) | (14 | ) | ||||||||||
| Interest expense, net | 138 | 49 | (5 | ) | (l) | 182 | ||||||||||||
| Loss on early retirement of debt | 22 | - | - | 22 | ||||||||||||||
| (Loss) income before income taxes | (5,293 | ) | 268 | (81 | ) | (5,106 | ) | |||||||||||
| Income tax (benefit) expense | (1,894 | ) | 71 | (22 | ) | (k), (m) | (1,845 | ) | ||||||||||
| Earnings from equity method investments, net of tax | - | 10 | (10 | ) | (k) | - | ||||||||||||
| Net (loss) income, including non-controlling interest | (3,399 | ) | 207 | (70 | ) | (3,262 | ) | |||||||||||
| Net (income) attributable to noncontrolling interest | (9 | ) | (9 | ) | - | (18 | ) | |||||||||||
| Net (loss) income attributable to the company | $ | (3,408 | ) | $ | 198 | $ | (70 | ) | $ | (3,280 | ) | |||||||
| Basic and diluted earnings per share | $ | (16.65 | ) | $ | (15.87 | ) | ||||||||||||
| Basic and diluted weighted common average shares outstanding | 205 | 2 | (n) | 207 | ||||||||||||||
Unaudited Condensed Combined Pro Forma Statement of Operations
Three Months Ended December 31, 2020
(in millions, except per share information)
AmerisourceBergen Corporation | Alliance Healthcare | Pro Forma Adjustments | Notes | Pro Forma Combined | ||||||||||||||
| Revenue | $ | 52,517 | $ | 5,246 | $ | - | $ | 57,763 | ||||||||||
| Cost of goods sold | 51,064 | 4,737 | - | 55,801 | ||||||||||||||
| Gross profit | 1,453 | 509 | - | 1,962 | ||||||||||||||
| Operating expenses: | ||||||||||||||||||
| Distribution, selling, and administrative | 735 | 386 | - | 1,121 | ||||||||||||||
| Depreciation and amortization | 100 | 37 | 23 | (e) | 160 | |||||||||||||
| Employee severance, litigation, and other | 70 | - | - | 70 | ||||||||||||||
| Impairment of PharMEDium assets | - | - | - | - | ||||||||||||||
| Operating income | 548 | 86 | (23 | ) | 611 | |||||||||||||
| Other (income) loss | (14 | ) | - | (10 | ) | (o) | (24 | ) | ||||||||||
| Interest expense, net | 34 | 11 | - | (p) | 45 | |||||||||||||
| Loss on early retirement of debt | - | - | - | - | ||||||||||||||
| Income before income taxes | 528 | 75 | (14 | ) | 589 | |||||||||||||
| Income tax expense | 149 | 20 | (4 | ) | (o), (q) | 165 | ||||||||||||
| Earnings from equity method investments, net of tax | - | 7 | (7 | ) | (o) | - | ||||||||||||
| Net income, including non-controlling interest | 379 | 62 | (17 | ) | 424 | |||||||||||||
| Net (income) attributable to noncontrolling interest | (4 | ) | (4 | ) | - | (8 | ) | |||||||||||
| Net income attributable to the company | $ | 375 | $ | 58 | $ | (17 | ) | $ | 416 | |||||||||
| Basic earnings per share | $ | 1.83 | $ | 2.01 | ||||||||||||||
| Diluted earnings per share | $ | 1.81 | $ | 1.99 | ||||||||||||||
| Basic weighted common average shares outstanding | 205 | 2 | (r) | 207 | ||||||||||||||
| Diluted weighted common average shares outstanding | 207 | 2 | (r) | 209 | ||||||||||||||
Notes to Unaudited Condensed Combined Pro Forma Financial Information
(in millions)
Note 1 - Basis of presentation
The unaudited condensed combined pro forma financial statements are based on AmerisourceBergen Corporation's (the "Company's") and a majority of Walgreen Boots Alliance's ("WBA's") Alliance Healthcare businesses ("Alliance Healthcare") historical financial statements as adjusted to give effect to the proposed acquisition of Alliance Healthcare and the debt issuance necessary to finance a portion of the acquisition. The Company's historical results reflect its unaudited balance sheet as of December 31, 2020, unaudited statement of operations for the three months ended December 31, 2020, and audited statement of operations for the fiscal year ended September 30, 2020. The Alliance Healthcare historical results reflect its unaudited balance sheet as of November 30, 2020, unaudited statement of operations for the three months ended November 30, 2020, and audited statement of operations for the fiscal year ended August 31, 2020. Alliance Healthcare’s historical combined financial statements have been prepared on a stand-alone basis and reflect a combination of entities and portions of certain entities under common control that have been “carved out” of and derived from WBA’s historical consolidated financial statements and accounting records. As a result, the Alliance Healthcare historical financial statements may not necessarily reflect what its financial condition and results of operation would have been had Alliance Healthcare been an independent, stand-alone entity during the periods presented. The unaudited condensed combined pro forma statements of operations for the three months ended December 31, 2020 and the twelve months ended September 30, 2020 give effect to the Alliance Healthcare acquisition as if it had occurred on October 1, 2019. The unaudited condensed combined pro forma balance sheet as of December 31, 2020 gives effect to the Alliance Healthcare acquisition as if it had occurred on December 31, 2020. These unaudited condensed combined pro forma financial statements are presented for illustrative purposes only and do not necessarily reflect the operating results or financial position that would have occurred if the Alliance Healthcare acquisition had been consummated on the dates indicated, nor is it necessarily indicative of the results of operations or financial condition that may be expected for any future period or date. Accordingly, such information should not be relied upon as an indicator of future performance, financial condition or liquidity.
Based on a preliminary review of the accounting policies of the Company and Alliance Healthcare, the Company is not aware of any difference that would have a material impact on the unaudited condensed combined pro forma financial statements. After the completion of the Alliance Healthcare acquisition, as more information becomes available, accounting policy differences may be identified and these differences, when identified, could have a material impact on the unaudited pro forma financial statements.
Note 2 - Preliminary purchase price allocation
In January 2021, the Company entered into a share purchase agreement with WBA pursuant to which the Company will acquire a majority of WBA's Alliance Healthcare businesses for approximately $6.5 billion, comprised of $6.275 billion in cash, subject to certain purchase price adjustments, and two million shares of Company common stock (the "Transaction"). WBA's operations in China, Italy, and Germany are not part of the Transaction. The Company intends to finance the acquisition of Alliance Healthcare using a combination of cash, a bank term loan, and the issuance of senior notes. The Transaction, which is expected to close by AmerisourceBergen’s fiscal year-end 2021, is subject to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals.
The unaudited condensed combined pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of the assets acquired and the liabilities assumed of Alliance Healthcare based on management's best estimates of fair value. The final purchase price allocation may vary based upon final appraisals, valuations, and analyses of the fair value of the assets acquired and assumed liabilities and is subject to change. Accordingly, the pro forma adjustments are preliminary and have been made solely for illustrative purposes.
The following table illustrates the preliminary allocation of the purchase price for Alliance Healthcare to the acquired identifiable assets, assumed liabilities, and pro forma goodwill:
| Total purchase price | $ | 6,503 | ||
| Accounts receivable | 3,337 | |||
| Inventories | 1,701 | |||
| Prepaid expenses and other | 306 | |||
| Due from Walgreen Boots Alliance | 265 | |||
| Property and equipment | 547 | |||
| Intangible Assets | 2,211 | |||
| Other assets | 504 | |||
| Total identifiable assets | 8,871 | |||
| Accounts payable | (4,642 | ) | ||
| Accrued expenses and other | (704 | ) | ||
| Due to Walgreen Boots Alliance | (53 | ) | ||
| Deferred tax liability | (586 | ) | ||
| Other liabilities | (270 | ) | ||
| Total liabilities assumed | (6,255 | ) | ||
| Total pro forma goodwill | $ | 3,887 |
The estimated intangible assets acquired include customer relationships, with an estimated useful life of 13 years, and a tradename, with an estimated useful life of 10 years. The final estimated lives assigned to these intangible assets may vary based upon final valuations. Accordingly, the pro forma amortization adjustments are preliminary and have been made solely for illustrative purposes.
Note 3 - Pro forma adjustments
Alliance Healthcare’s combined financial statements include allocation of corporate costs incurred by WBA, for services that are provided to or on behalf of Alliance Healthcare, using consistent and reasonable method based on gross profit metric. The historical statements of operations for Alliance Healthcare reflect allocations of corporate costs from WBA for shared services and infrastructure provided, which includes costs such as information technology, accounting, legal, risk and insurance services, treasury, shareholder services and other corporate and infrastructure services. The allocations may not; however, be indicative of the actual expenses that would have been incurred during the periods presented if Alliance Healthcare historically operated as a separate, stand-alone entity.
Following the Alliance Healthcare acquisition, certain functions such as information technology and infrastructure will be performed by the Company or third-party service providers. For an interim period, however; some of these functions may continue to be provided by WBA under transition service agreements. The costs for these services could in the aggregate be higher than the combination of the Company’s current costs and those reflected in the historical financial statement of Alliance Healthcare.
The pro forma adjustments are based on our preliminary estimates and assumptions that are subject to change. The following adjustments have been reflected in the unaudited condensed combined pro forma financial information:
Adjustments to the condensed combined pro forma balance sheet:
| (a) | Reflects the following adjustments: |
| (1) | reduction of approximately $6,275 million to reflect the estimated cash portion of the purchase price in connection with the Alliance Healthcare acquisition; |
| (2) | reduction of $151 million to reflect the historical cash retained by the seller; |
| (3) | increase of approximately $3,009 million to reflect the estimated net proceeds from a $1,000 million term loan borrowing and the issuance of $2,025 million of senior notes to partially fund the cash portion of the purchase price in connection with the Alliance Healthcare acquisition. |
| (b) | Represents the elimination of the portion of due to/from Walgreen Boots Alliance included in the historical financial statements of Alliance Healthcare that is not related to trade acccounts receivable or trade accounts payable. |
| (c) | The Company has not yet determined the fair value of property and equipment acquired; therefore, carrying value has been used in the preliminary purchase price allocation and in the pro forma financial information. |
| (d) | Represents the following adjustments: (1) reduction of $3,282 million representing goodwill included in the historical November 30, 2020 balance sheet of Alliance Healthcare, and (2) and increase of $3,887 million to reflect the estimated goodwill in connection with the Company's preliminary purchase price allocation for the Alliance Healthcare acquisition. |
| (e) | Reflects the adjustment of historical intangible assets acquired by the Company to their estimated fair values. As part of the preliminary valuation analysis, the Company identified intangible assets, including trade names and customer relationships. |
The following table summarizes the estimated fair value of Alliance Healthcare's identifiable intangible assets and their estimated useful lives and uses a straight-line method of amortization (the sum of the components may not equal the total due to rounding):
| Three months ended | ||||||||||||||||
| Fiscal 2020 | December 31, 2020 | |||||||||||||||
| Estimated | Estimated Useful | Amortization | Amortization | |||||||||||||
| Fair Value | Life in Years | Expense | Expense | |||||||||||||
| Trade names | $ | 300 | 10.0 | $ | 30 | $ | 8 | |||||||||
| Customer relationships | 1,911 | 13.0 | 147 | 37 | ||||||||||||
| $ | 2,211 | 177 | 44 | |||||||||||||
| Historical amortization expense | (77 | ) | (21 | ) | ||||||||||||
| Pro forma adjustments | $ | 100 | $ | 23 | ||||||||||||
These preliminary estimates of fair value and estimated useful lives will likely differ from the final amounts the Company will calculate after completing a detailed valuation analysis, and the difference could have a material effect on the accompanying unaudited condensed combined pro forma financial statements. A 10% change in the valuation of intangible assets would cause a corresponding increase or decrease in the balance of goodwill and annual amortization expense of approximately $18 million, assuming an overall weighted-average useful life of 12.6 years.
| (f) | Represents an estimate of the transaction costs expected to be incurred in connection with the Transaction. |
| (g) | Represents a reduction of $375 million to the short-term debt balance included in the historical November 30, 2020 balance sheet of Alliance Healthcare that will be retained by the seller. |
| (h) | Represents an increase of $3,009 million to reflect the long-term debt, net of anticipated debt offering costs, that is expected to be incurred to partially fund the acquisition of Alliance Healthcare. |
| (i) | Represents the following adjustments: (1) a reduction of $130 million to the deferred tax liability balance included in the historical November 30, 2020 balance sheet of Alliance Healthcare, and (2) an increase of $586 million to reflect the estimated deferred tax liabilities in connection with the Company's preliminary purchase price allocation for the Alliance Healthcare acquisition, which is subject to change based on the final purchase price allocation. |
| (j) | Represents the following adjustments: (1) elimination of the stockholders' equity balances included in the historical November 30, 2020 balance sheet of Alliance Healthcare, and (2) the increase of an estimated $228 million related to the issuance of 2 million AmerisourceBergen Corporation shares, with a per share fair value of $113.86 as of March 15, 2021, to finance a portion of the purchase price in connection with the closing of the Alliance Healthcare acquisition. A 10% change in the stock price of AmerisourceBergen Corporation would cause the total purchase price to increase or decrease by $23 million, which would offset the estimated goodwill. |
Adjustments to the condensed combined pro forma statements of operations:
| (k) | Reclass $10 million of Alliance Healthcare's historical Earnings from equity method investments, net of tax to Other (income) loss, $14 million income, and Income tax expense, $4 million, in the condensed combined pro forma statements of operations. |
| (l) | Represents the following adjustments: (1) elimination of Alliance Healthcare's historical interest expense of $49 million, and (2) an increase of $44 million to reflect the estimated interest expense, assuming a 1.295% weighted average interest rate, associated with the estimated long-term debt that is expected to be incurred to partially fund the acquisition of Alliance Healthcare. A 10-basis point increase in the assumed interest rate would increase interest expense by $3 million. |
| (m) | Reflects the income tax effect of the pro forma adjustments based on the estimated statutory rate of 26.5% |
| (n) | Represents an adjustment to the Company's basic and diluted weighted average common shares outstanding to include an incremental two million shares expected to be issued in connection with the Alliance Healthcare acquisition. |
| (o) | Reclass $7 million of Alliance Healthcare's historical Earnings from equity method investments, net of tax to Other (income) loss, $10 million income, and Income tax expense, $3 million, in the condensed combined pro forma statements of operations. |
| (p) | Represents the following adjustments: (1) elimination of Alliance Healthcare's historical interest expense of $11 million, and (2) an increase of $11 million to reflect the estimated interest expense, assuming a 1.295% weighted average interest rate, associated with the estimated long-term debt that is expected to be incurred to partially fund the acquisition of Alliance Healthcare. A 10-basis point increase in the assumed interest rate would increase interest expense by $1 million. |
| (q) | Reflects the income tax effect of the pro forma adjustments based on the estimated statutory rate of 26.5% |
| (r) | Represents an adjustment to the Company's basic and diluted weighted average common shares outstanding to include an incremental two million shares expected to be issued in connection with the Alliance Healthcare acquisition. |
